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                                                          ABSTRACT  
Orally  disintegrating  tablets  (ODTs)  are  getting    popularity  over  conventional  tablets  due  
to their  convenience  in  administration  and  suitability  for  patients  having  dysphagia  
(difficulty  in swallowing).  There  is  an  increasing  demand  for  more  patient  compliance   
dosage  form  and  a  novel  method  is  the    development  orally  disintegrating  tablets  which  
dissolve  or  disintegrates  instantly  on  the  patient  tongue  or  buccal  mucosa.  It  is  suited  for  
tablets  undergoing high first pass metabolism and is used for improving  bioavailability with 
reducing dosing frequency to  minimize  side  effect  and  make  it  more  cost  effective.  
Zolmitriptan is a selective serotonin receptor agonist. The  absolute bioavailability  is  only  
approximately  40%  due  to  extensive  hepatic  first  pass   metabolism (CYP1A2-mediated). 
Hence the main objective of the study was to formulate oral disintegrating tablets  of    
Zolmitriptan  to  achieve  a  better  dissolution  rate  and  further  improving  the  bioavailability  
of  the  drug. Orally  disintegrating tablets prepared by direct compression and using, 
Crosspovidone, Crosscarmellose sodium, Sodium  starch  glycolate, Mannitol ,Magnesium  
stearate, Talc, Aerosil, Citric acid   were  prepared  and  evaluated  for  the  precompression  
parameters  such  as  bulk  density,  tapped density,  compressibility index ,  angle  of  repose  
etc.  The prepared batches of tablets were evaluated for hardness, weight variation, friability, 
disintegration time and in-vitro dissolution  profile  and  found  satisfactory.  Among  these  
groups,  F6 Formulation  is  the  best  formulation  and  showed  maximum  dissolution rate with 
drug  release within 10 minutes (94.4%) and it containing Crosspovidone as a superdisintegrant 
showed minimum disintegration time 15 seconds.   
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                                            1. INTRODUCTION                                                                                 
 
            Oral disintegration tablets are the novel technology for administration of the drug through 
the oral route. The tablet is the most widely used dosage form because of its convenience in 
terms of self -administration, compactness and ease in manufacturing. However, many patients 
especially children and elderly have difficulty in swallowing tablets and capsules and 
consequently unable to take medicine as prescribed. Almost 50% of the population is affected by 
such problem, resulting in the high incidence of non compliance and infective therapy. To 
overcome such problems, fast disintegrating tablets or orally disintegrating tablets have emerged 
as an alternative dosage forms.  
 
           Oral disintegrating tablets’s are solid unit dosage forms, which disintegrate or dissolve 
rapidly in the mouth without chewing and water. An Oral disintegration tablets is a solid dosage 
form that disintegrates and dissolves in the mouth without water within 60 seconds or less. 
Orally disintegrating tablets provide an advantage particularly for pediatric and geriatric 
populations who have difficulty in swallowing conventional tablets and capsules. ODTs may 
show increased oral bioavailability. It provides good stability, accurate dosing, easy 
manufacturing, small packaging size, and easy to handle by patients.  
 
           A solid dosage form containing medicinal substance or active ingredient which 
disintegrates rapidly usually within a matter of seconds when placed upon the tongue.”Orally 
disintegrating tablets have been found to be the choice for Psychiatric as well as patient suffering 
from stroke, thyroid disorder, Parkinson’s diseases and multiple sclerosis, patients with nausea, 
vomiting and motion sickness. These systems are also called melt‐in‐mouth tablets, Rapid melts, 
porous tablets, Oro dispersible, quick dissolving or rapidly disintegrating tablets (1-7). 
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                                         Fig.1 oral disintegrating tablets                             
                                                    
              In today’s era many people are suffering from migraine. Migraine is a one sided throbbing 
headache followed by neurological and visual disturbances. Attack may prolong for long period. 
Patients routinely report the pain of an attack as being the most severe they have ever experienced, 
or Migraine is often disabling neurovascular disorder. Changes in the metabolism and the central 
processing of serotonin, as well as abnormalities in the modulation of the central and peripheral 
trigeminal nociceptive pathways, have been shown to play significant roles in migraine 
pathophysiology. Recent evidence suggests that a low serotonin state facilitates activation of the 
trigeminal nociceptive pathways. In addition, several pharmacological agents that modulate 
serotonin are used in the treatment of migraine. Specifically there are seven FDA approved, 5-
hydroxytryptamine (5-HT) 1B/1D receptor agonists, used for the acute abortive therapy of 
migraine. Zolmitriptan is one such triptan. 
 
              Zolmitriptan is a second-generation triptan prescribed for patients with migraine attacks, 
with and without an aura, and cluster headaches. It has a selective action on serotonin receptors 
and is very effective in reducing migraine symptoms, including pain, nausea and photo or 
photophobia. It is currently available as a conventional tablet, an oral disintegrating tablet and a 
nasal spray (2.5 mg and 5 mg) per dose. The absolute bioavailability of  zolmitriptan is up to 
(40%- 50%) for both oral and nasal dosage forms. The faster clearance of the drug from the nasal 
cavity could explain the low bioavailability. The half-life of the Zolmitriptan is 2.5 to 3 hrs and it 
undergoes hepatic metabolism. In the present study we intend to prepare oral disintegrating tablet 
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of Zolmitriptan (2.5 mg) in order to improve the bioavailability and efficacy by using 
Crosscarmellose sodium, Sodium starch glycolate, Crosspovidone as disintegrates. Recent 
developments in technology have presented viable dosage alternatives for pediatric, geriatric, 
bedridden, nauseous or non-compliant patients, who face difficulty in swallowing or chewing solid 
dosage forms and are unwilling to take solid preparations due to a fear of choking. Hence, mouth 
dissolving/disintegrating tablets are a perfect fit for them. Super disintegrates added in the 
formulation increase the drug release, thus increasing the bioavailability of drug. Mouth 
disintegrating tablets when placed in the mouth, disintegrate instantaneously, releasing the drug, 
which dissolves or disperses in the saliva and can be swallowed as a liquid, without the aid of 
water. Some drugs are absorbed from the mouth, pharynx and esophagus as the saliva passes down 
into the stomach. In such cases, bioavailability of drug is significantly greater than that observed 
from conventional tablet dosage form. This system of drug delivery allows children, elderly, and 
the general population to take their medications discretely wherever and whenever needed, much 
eliminating the factor of patient non-compliance. The benefits, in terms of patient compliance, 
rapid onset of action, increased bioavailability, and good stability make these tablets popular as a 
dosage form of choice in the current market (8). 
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1.1 Oral Disintegrating Tablets 
Dysphasia or difficulty in swallowing is common among all age groups. According to studies    
dysphagia is common in about 35% of general population. 
   Common complaints about difficulty in swallowing tablets  
•  Size 
•  Surface 
•  Form 
•  Taste of tablets 
 
Definition 
An ODT is a solid dosage form that disintegrates and dissolves in the mouth (either on or     
beneath the tongue or in the buccal cavity without water within 60 seconds or less.                                          
The US Food and Drug Administration Center for Drug Evaluation and Research (CDER) defines 
 an ODT as "A solid dosage form containing medicinal substances, which disintegrates rapidly, 
usually within a matter of seconds, when placed upon the tongue. (8)                                                   
 The European Pharmacopoeia however defines a similar term, oro-disperse, as a tablet that can be 
placed in the mouth where it disperses rapidly before swallowing. (9) 
 
 
   Advantanges (10): 
• Ease of Administration to the patient who cannot swallow, such as the elderly, stroke victims,    
bedridden patients, patient affected by renal failure and patient who refuse to swallow such as 
pediatric, geriatric & psychiatric patients. 
• No need of water to swallow the dosage form, which is highly convenient feature for patients 
who are traveling and do not have immediate access to water. 
• Rapid dissolution and absorption of the drug, which will produce quick onset of action. 
• Some drugs are absorbed from the mouth, pharynx and esophagus as the saliva passes down 
into the stomach. In such cases bioavailability of drug is increased. 
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• Pregastric absorption can result in improved bioavailability and as a result of reduced dosage;   
improve clinical performance through a reduction of unwanted effects. 
• Good mouth feel property helps to change the perception of medication as bitter pill particularly   
in pediatric patient. 
• The risk of chocking or suffocation during oral administration of conventional formulation 
    due to physical obstruction is avoided, thus providing improved safety. 
• New business opportunity like product differentiation, product promotion, patent extensions 
    and life cycle management. 
• Beneficial in cases such as motion sickness, sudden episodes of allergic attack or  coughing,   
where an ultra rapid onset of action required. 
•  An increased bioavailability, particularly in cases of insoluble and hydrophobic drugs, due to   
rapid disintegration and dissolution of these tablets. 
  Stability for longer duration of time, since the drug remains in solid dosage form till it is 
consumed. So, it combines advantage of solid dosage form in terms of stability and liquid 
dosage form in terms of bio availability. 
 
 
                                  
                                             Fig 2 showing advantages of ODTs 
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Ideal Characteristics of Oral disintegration tablets. (11,12) 
ODTs should depict some ideal characteristics to distinguish them from traditional conventional 
dosage forms. Important desirable characteristics of these dosage forms include (Kuchekar et al, 
2003). 
1. No water requirement for swallowing purpose but it should dissolve or disintegrate in the    
mouth usually within fraction of seconds.  
2.  Provide pleasant feeling in the mouth.  
3.  Be compatible with taste masking.  
4.  Be portable without fragility concern.  
5.  Leave negligible or no residue in the mouth after oral administration. 
6.  Exhibit low sensitivity to altered environmental conditions such as humidity and temperature.  
7.  Allow high drug loading.  
8. Adaptable and amenable to conventional processing and packaging equipment at nominal 
expense 
   .  
Various approaches employed in manufacture of Oral disintegrating tablets: 
There are number of techniques generally employed in the formulation of orally disintegrating  
dosage forms. These techniques have their own advantages as well as disadvantages and are  
described below:  
 
a) Freeze-drying (13]. 
This method is suitable for thermolabile drugs, since it does not employ heat in the manufacturing 
process. It is a process in which water is sublimated from the product after freezing. The product 
prepared using this method is highly porous and has a very high specific surface area, which 
dissolves rapidly when in contact with water [11, 19-20]. The disadvantages of this method besides 
producing fragile products, are the use of high cost equipment and complex processing steps, 
which limit the use of this method. 
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(b) Tablet moulding (14,15). 
Tablet moulding method uses water-soluble ingredients so that the tablets dissolve completely 
andrapidly. Moulding process includes moistening, dissolving, or dispersing of drug with a 
solvent. The powder blend is then moulded into tablets under pressure lower than that used in 
conventional tablet compression. Air drying process removes the solvent in the tablet. As a result, 
moulded tablets are very porous and less compact than compressed tablets. The ODT possesses 
porous structure that improves dissolution. 
 
(c) Sublimation (16) 
Sublimation is a manufacturing method which produces porous ODT with fast disintegration. Inert 
solid ingredients that volatilize readily (e.g. urea, ammonium carbonate, ammonium bicarbonate 
and camphor) are mixed with other tablet ingredients and the mixture is compressed into tablets. 
When the volatile materials are sublimated, an ODT with porous structures is produced . Kizumi et 
al. (1997) developed ODT utilizing camphor as subliming material. Camphor was sublimated in 
vacuum at 800C for 30 min after preparation of tablets. Hence, the tablet produced is highly 
porous with fast disintegration time. 
 
(d).Direct compression (16) 
Direst compression is the easiest and conventional way to manufacture ODT. The advantages of 
this method are low manufacturing cost, the use of conventional equipments and limited number of 
processing steps. However, the disintegration and dissolution of the ODT are slower due to the 
more compacted and less porous ODT formed. The disintegration of ODT manufactured using this 
method was dependent on Superdisintegrant, water soluble excipients and effervescing agents. 
 
(e) Spray drying (17) 
Spray drying technique produces highly porous and fine powders as the processing solvent is 
evaporated during this process. However, this method is not suitable for heat sensitive drugs. ODT 
manufactured using this method disintegrates within 20 seconds when immersed in an aqueous 
medium. Allen and Wang (1993) reported an example of ODT manufactured using this method 
[23]. Hydrolyzed and non-hydrolyzed gelatin were used as supporting matrix, mannitol as bulking 
agent, sodium starch glycolate as superdisintegrant, citric acid and sodium bicarbonate as 
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disintegration and dissolution enhancers. 
 
(f) Mass extrusion  
Mass extrusion involves softening of the active blend using a solvent mixture of water-soluble 
polyethylene glycol and methanol, and subsequent expulsion of soft mass through an extruder. The 
product is cut into even segment using heating blade. The dried cylinder can also be used to coat 
granules of bitter tasting drugs and there by masking their bitter taste.   
 
(g) Phase transition (18). 
Two sugar alcohols, one with high and one with low melting points are used to manufacture ODT. 
The ODT is compressed then heated at a temperature between the melting points of the two sugar 
alcohols. The tablet hardness was increased after heating process, due to increase of inter-particle 
or the bonding surface area in the tablets induced by phase transition of lower melting point sugar 
alcohol  
 
Superdisintegrants 
Disintegrants are substances routinely included in tablet formulations and in some hard shell 
capsule formulations to promote moisture penetration and dispersion of the matrix of dosage 
form in dissolution fluids. An oral solid dosage form should ideally disperse into the primary 
particles from which it was prepared . Superdisintegrants are generally used at a low 
concentration, typically 1-10% by weight relative to total weight of dosage unit. Generally 
employed superdisintegrants are croscarmellose sodium (Ac-Di-Sol), crospovidone (CP), sodium 
starch glycolate (SSG) etc. which represent example of crosslinked cellulose, crosslinked 
polymer and crosslinked starch respectively. Selection of appropriate formulation excipients and 
manufacturing technology is necessary for obtaining the optimized design features of orally 
disintegrating dosage forms. Ideally, superdisintegrants should cause the tablet to disrupt, not 
only into the granules from which it was compressed but also into powder particles from which 
the granules were prepared. 
 
 
Selection of superdisintegrants (19): 
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Although superdisintegrants primarily affect the rate of disintegration, but when used at 
high 
  levels they can also affect mouth feel, tablet hardness and friability. Hence, various ideal factors   
to be considered while selecting an appropriate Superdisintegrants for a particular formulation 
should contain 
1. Produce rapid disintegration, when tablet comes in contact with saliva in the mouth/oral 
       cavity. 
 2.   Be compactable enough to produce less friable tablets. 
 3.   Produce good mouth  feel to the patients. Thus, small particle size is preferred to achieve 
       patient compliance. 
4.    Have good flow, since it improves the flow characteristics of total blend. 
 
 Mechanism of action of disintegrant. (20,21,22,) 
Various mechanisms proposed in this concern include water wicking, swelling, deformation 
recovery, repulsion and heat of wetting. It seems likely that no single mechanism can explain 
the complex behavior of the disintegrants. However, each of these proposed mechanisms 
provides some understanding of different aspects of disintegrant action. 
 
Water wicking 
The ability of disintegrant to draw water into the porous network of tablet is essential for 
effective disintegration. On keeping the tablet into suitable aqueous medium, the medium 
enters into tablet and replaces the air adsorbed on the particles which weakens the 
intermolecular bonds and breaks the tablet into fine particles. Water uptake by tablet depends 
upon hydrophilicity of the drug/excipients and on tableting conditions. Unlike swelling, 
which is mainly a measure of volume expansion with accompanying force generation, water 
wicking is not necessarily accompanied by a volume increase. The ability of a system to draw 
water can be summarized by Washburn’s equation: 
         
                                             L2 = (γ Cosθ/2η) × rt 
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The Washburn equation is too simplistic to apply to a dynamic tablet-disintegration process, 
but it does show that any change in the surface tension (γ), pore size (r), solid-liquid contact 
angle (θ) or liquid viscosity (η) could change the water wicking efficiency. L is the length of 
water penetration in the capillary and t is the time. This process is also considered as capillary 
action method. 
 
Swelling 
Although water penetration is a necessary first step for disintegration, swelling is probably the 
most widely accepted mechanism of action for tablet disintegrants. For swelling to be 
effective as a mechanism of disintegration, there must be a superstructure against which 
disintegrants swells. Figure 2 represents the disintegration of tablet by wicking and swelling. 
Swelling of the disintegrant against the matrix leads to development of a swelling force. A 
large internal porosity in the dosage form in which much of the swelling can be 
accommodated reduces the effectiveness of the disintegrant. On the other hand, sufficient 
swelling force is exerted in the tablet with low porosity. It is worthwhile to note that if 
packing fraction is very high, fluid is unable to penetrate in the tablet and disintegration is 
again slowed down. 
 
                              Fig.3 Disintegration of Tablet by Wicking and Swelling 
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Heat of wetting 
When disintegrants with exothermic properties get wetted, localized stress is created due to 
capillary air expansion, which aids in disintegration of tablet. This explanation, however, is 
limited to only a few types of disintegrants and cannot describe the action of most modern 
disintegrating agents. 
 
Due to release of gases 
Carbon dioxide gets released within tablets on wetting due to interaction between bicarbonate 
and carbonate with citric acid or tartaric acid. The tablet disintegrates due to generation of 
pressure within the tablet. This effervescent mixture is used when pharmacist needs to formulate 
very rapidly dissolving tablets or fast disintegrating tablet. As these disintegrants are highly 
sensitive to small changes in humidity level and temperature, strict control of environment is 
required during preparation of the tablets. The effervescent blend is either added immediately 
prior to compression or can be added into two separate fractions of formulation. 
 
Particle repulsive forces 
This is another mechanism of disintegration that attempts to explain the swelling of tablet made 
with non-swellable disintegrants. Guyot-Hermann proposed a particle-particle repulsion theory 
to explain the observation that particles which do not swell extensively such as starch, could still 
disintegrates tablets. According to this theory, water penetrates into tablet through hydrophilic 
pores and a continuous starch network is created that can convey water from one particle to the 
next, imparting a significant hydrostatic pressure. The water then penetrates between starch 
grains because of its affinity for starch surfaces, thereby breaking hydrogen bonds and other 
forces holding the tablet together. The electric repulsive forces between particles are the 
mechanism of disintegration and water is required for it. 
 
Deformation recovery 
Deformation recovery theory implies that the shape of disintegrant particles is distorted during 
compression and the particles return to their precompression shape upon wetting, thereby 
causing the tablet to break apart. Such a phenomenon may be an important aspect of the 
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mechanism of action of disintegrants such as crospovidone and starch that exhibit little or no 
swelling. Disintegration of tablet by deformation as well as repulsion is illustrated in Figure 3 
                   
 
                    Fig: 4  Disintegration of tablets by deformation and repulsion method. 
 
By enzymatic reaction 
Enzymes present in the body also act as disintegrants. These enzymes dearth the binding 
action of binder and  helps in disintegration. Due to swelling, pressure is exerted in the outer 
direction that causes the tablet to burst or the accelerated absorption of water leads to an 
enormous increase in the volume of granules to promote disintegration. 
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2.  REVIEW OF LITERATURE 
 
A. A. Kalanuria et.al (23) Migraine is a common and often disabling neurovascular 
disorder. Changes in the metabolism and the central processing of serotonin, as well as 
abnormalities in the modulation of the central and peripheral trigeminal nociceptive pathways, 
have been shown to play significant roles in migraine pathophysiology. Recent evidence 
suggests that a low serotonin state facilitates activation of the trigeminal nociceptive pathways. 
In addition, several pharmacological agents that modulate serotonin are used in the treatment of 
migraine. Specifically there are seven FDA approved, 5-hydroxytryptamine (5-HT) 1B/1D 
receptor agonists, used for the acute abortive therapy of migraine. Zolmitriptan is one such 
triptan. Zolmitriptan is available as a tablet, orally disintegrating tablet and as a nasal spray. It is 
rapidly absorbed and detectable within the plasma, within 2 to 5 minutes for the nasal spray and 
within 15 minutes for the tablet. Zolmitriptan reaches peak plasma levels in 2–4 hours, with good 
levels maintained for up to 6 hours. Although the metabolism of zolmitriptan is predominantly 
hepatic, only 25% of zolmitriptan is bound to plasma proteins. Thus it is unlikely for drug 
interactions involving the displacement of highly protein-bound drugs. Zolmitriptan is very well 
tolerated with less than half of participants in clinical trials reporting adverse events, most of 
which were mild and transient. Although rare, serious cardiovascular events have been reported 
with all triptans. However, when patients are appropriately selected, zolmitriptan is both, a safe 
and effective acute migraine abortive agent. In this article, we will first briefly review the 
biological role of serotonin and the literature linking serotonin to migraine pathophysiology. This 
will be followed by a comprehensive review of the pharmacodynamics, pharmacokinetics and 
efficacy of zolmitriptan. Finally, the clinical application of the use of zolmitriptan in migraine 
therapy will be discussed. 
 
Benjamin et.al (24) Migraine headache is a common and potentially debilitating disorder 
often treated by family physicians. Before diagnosing migraine, serious intracranial pathology 
must be ruled out. Treating acute migraine is challenging because of substantial rates of 
nonresponse to medications and difficulty in predicting individual response to a specific agent or 
dose. Data comparing different drug classes are relatively scarce. Abortive therapy should be 
used as early as possible after the onset of symptoms. Effective first-line therapies for mild to 
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moderate migraine are nonprescription nonsteroidal anti-inflammatory drugs and combination 
analgesics containing acetaminophen, aspirin, and caffeine. Triptans are first-line therapies for 
moderate to severe migraine, or mild to moderate migraine that has not responded to adequate 
doses of simple analgesics. Triptans should be avoided in patients with vascular disease, 
uncontrolled hypertension, or hemiplegic migraine. Intravenous antiemetics, with or without 
intravenous dihydroergotamine, are effective therapies in an emergency department setting. 
Dexamethasone may be a useful adjunct to standard therapy in preventing short-term headache 
recurrence. Intranasal lidocaine may also have a role in relief of acute migraine. Isometheptene-
containing compounds and intranasal dihydroergotamine are also reasonable therapeutic options. 
Medications containing opiates or barbiturates should be avoided for acute migraine. During 
pregnancy, migraine may be treated with acetaminophen or nonsteroidal anti-inflammatory drugs 
(prior to third trimester), or opiates in refractory cases. Acetaminophen, ibuprofen, intranasal 
sumatriptan, and intranasal zolmitriptan seem to be effective in children and adolescents, 
although data in these age groups are limited. 
 
Vollono C et.al (25) Abortive drugs used for migraine in children and adolescents are 
usually the same as those used in adults. Only a few studies have assessed the efficacy of triptans 
other than sumatriptan in pediatric migraine. This systematic review describes the evidence 
concerning the efficacy and tolerability of these triptans. The PubMed research produced 481 
results and only seven studies were randomized controlled trials. A total of 11 articles were 
reviewed. Zolmitriptan and rizatriptan were superior to placebo in most studies. Almotriptan 
demonstrated a high profile of tolerability. A single study of eletriptan demonstrated no 
statistical difference between this drug and placebo in terms of both efficacy and tolerability. All 
studies have reported a good triptan safety profile. The conflicting data regarding triptan efficacy 
are probably due to differences in populations, methodologies and efficacy measures among the 
different studies. Triptans are an important option in the symptomatic treatment of childhood and 
adolescent migraine. 
 
Eiland et.al (26) Migraine headaches frequently occur in the pediatric population, with a 
prevalence of 3% in children 2-7 years of age, 4-11% in children 7-11 years of age, and 8-23% in 
children 11 years of age and older. Migraine without aura is more than twice as common as 
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migraine with aura in children. Headaches are the third leading cause of emergency room 
referrals and rank in the top five health problems of children. The 2004 American Academy of 
Neurology's treatment parameter for migraine in children and adolescents recommended that 
nasal sumatriptan be considered for acute treatment; however, data were lacking to make a 
decision regarding the available oral triptans at that time. The more recently released European 
guidelines discuss three different triptans for use in children but no specific triptan was 
recommended. Currently, six of the seven available triptans have been studied for efficacy and 
safety in the pediatric population; however, only a few well controlled clinical studies have been 
conducted. Sumatriptan has the most available data on outcomes in general, with nasal 
sumatriptan showing the most positive results. Nasal sumatriptan is approved in children older 
than 12 years of age in Europe. Oral sumatriptan does not show any clinical benefit versus 
placebo in children. Rizatriptan and zolmitriptan have conflicting efficacy and safety data, with 
most studies favoring the use of oral rizatriptan and nasal zolmitriptan. Almotriptan is the first 
triptan to obtain a US FDA indication in adolescents with migraines lasting 4 or more hours. 
This approval was based upon two studies, one large clinical trial and one very small, open-label, 
pilot study. At this time, there are insufficient data to recommend naratriptan and eletriptan for 
first- or second-line use in pediatric patients with migraines. There are currently no efficacy data 
for frovatriptan in pediatric patients, which limits its use in this population. Adverse effects of 
triptans and pharmacokinetic data in children and adolescents are similar to those in adults. The 
triptan class should be considered as an acute treatment option for children and adolescents with 
migraines, although their use is mostly 'off-label'. Of the available triptans, there are more 
positive efficacy data for sumatriptan and zolmitriptan nasal sprays, and rizatriptan and 
almotriptan tablets than for the other triptans. 
 
Johnston et.al (27) Migraine is a chronic, recurrent, disabling condition that affects 
millions of people in the US and worldwide. Proper acute care treatment for migraineurs is 
essential for a full return of function and productivity. Triptans are serotonin (5-HT)(1B/1D) 
receptor agonists that are generally effective, well tolerated and safe. Seven triptans are available 
worldwide, although not all are available in every country, with multiple routes of 
administration, giving doctors and patients a wide choice. Despite the similarities of the available 
triptans, pharmacological heterogeneity offers slightly different efficacy profiles. All triptans are 
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superior to placebo in clinical trials, and some, such as rizatriptan 10 mg, eletriptan 40 mg, 
almotriptan 12.5 mg, and zolmitriptan 2.5 and 5 mg are very similar to each other and to the 
prototype triptan, sumatriptan 100 mg. These five are known as the fast-acting triptans. Increased 
dosing can offer increased efficacy but may confer a higher risk of adverse events, which are 
usually mild to moderate and transient in nature. This paper critically reviews efficacy, safety 
and tolerability for the different formulations of sumatriptan, zolmitriptan, rizatriptan, 
naratriptan, almotriptan, eletriptan and frovatriptan. 
 
Francis et.al (28) Cluster headache (CH) is a rare and disabling primary headache 
disorder. CH attacks are unilateral, short, severe headaches associated with ipsilateral autonomic 
symptoms that occur in a periodic fashion. We provide a systematic review and meta-analysis of 
existing trials of pharmacotherapy for CH and evidence-based suggestions for acute abortive 
treatment and preventive therapy for cluster headache. Prospective, double-blind, randomized 
controlled trials of any pharmacologic agent for the symptomatic relief or prevention of CH were 
included in this evidence-based review. The main outcomes considered were headache response 
and pain-free response at 15 and 30 minutes for acute treatment trials, and the cessation of CH 
attacks within a specific time period or the number of days on which CH attacks occurred for 
preventive trials. Twenty-seven trials were included in the analysis. The American Academy of 
Neurology quality criteria were used to assess trial quality and to grade advisements. Based on 
the evidence, for acute treatment of CH, Level A advice can be given for subcutaneous 
sumatriptan 6 mg, zolmitriptan nasal spray 5 mg and 10 mg, and 100% oxygen 6-12 L/min. 
Level B advice can be given for sumatriptan nasal spray 20 mg and oral zolmitriptan 5 mg and 
10 mg. For the prevention of CH, Level B advice can be given for intranasal civamide 100 
microg daily and suboccipital steroid injections, and Level C advice can be given for verapamil 
360 mg, lithium 900 mg, and melatonin 10 mg. 
 
Majumdar et.al (29) Cluster headache is a primary headache disorder with the distinct 
clinical features: unilaterality, extreme pain, cranial autonomic features and periodicity. The 
prevalence of the disorder is 0.1% in adults and with a male predominance. The age of onset is 
usually in the second and third decade of life but the onset in the first decade is recognised. We 
describe our experience of cluster headache in children and review the literature. We have 
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attempted to define the clinical features of cluster headache in children as compared to adults, the 
role of clinical investigations, reliability of clinical diagnosis, effective treatment and 
management. 
 
Fotuhi et.al (30) Vestibular migraine (VM), also known as migraine-associated vertigo, is 
a common cause of dizziness in adults. We performed a comprehensive literature search 
regarding treatment for VM or migraine-associated vertigo during the period of 1990-2008 and 
used, individually or in combination, the search terms VM, migraine-associated vertigo, 
migraine-associated dizziness, migrainous vertigo, migraine and vertigo, migraine and 
disequilibrium, and headache and vertigo. We found nine publications that address treatment 
strategies for VM. One small randomized clinical trial found some benefit from the use of 
zolmitriptan for abortive treatment of VM. The other eight observational studies showed 
marginal improvement with migraine prophylactic medications such as nortriptyline, verapamil, 
or metoprolol. Until more specific treatment options become available, patients with VM need to 
be managed with similar prophylactic and abortive strategies as those used for migraine in 
adults. 
 
Tyagi et.al (31) Cluster headache (CH) is a strictly unilateral headache that occurs in 
association with cranial autonomic features. It is an excruciating syndrome and is probably one 
of the most painful conditions known to exist, with some female patients describing each attack 
as being worse than childbirth. CH responds to specific therapies, thereby underlying the 
importance of distinguishing it from other primary headache syndromes and initiating 
appropriate treatments. This article reviews the evidence base for the medical treatments used in 
ICH. 
 
Silver, Shawna et.al (32) To undertake a meta-analysis of all randomised controlled trials 
(RCTs) on the acute pharmacologic treatment of children and adolescents with migraine 
headache.the methods used totally, 139 abstracts of clinical trials specific to the acute treatment 
of paediatric migraine were appraised. Inclusion criteria required clinical trials to be randomised, 
blinded, placebo-controlled studies with comparable endpoints. Non- English language 
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publications were excluded. 11 clinical trials qualified for inclusion in the final meta-analysis. 
Two endpoints were analysed: the proportion of patients with (1) headache relief, and (2) 
complete pain relief, 2 h post-treatment. And the conclusion Despite the pharmacological options 
for the management of acute migraine, few RCTs in the paediatric population exist. Composite 
data demonstrate that only ibuprofen and sumatriptan are significantly more effective than 
placebo in the generation of headache relief in children and adolescents. 
 
Peterlin, B Lee et.al (33) Migraine is a common, often disabling, neurovascular disease 
that has been shown to be associated with abnormal serotonergic activity. Drugs that modulate 
serotonin receptors are commonly used in the acute treatment of a migraine attack. Zolmitriptan, 
a 5-hydroxytryptophan(1B/1D) receptor agonist, is once such drug that is used in acute migraine 
therapy. Zolmitriptan is FDA approved for the treatment of acute migraine attacks and there is 
recent literature demonstrating its efficacy in the acute treatment of cluster attacks. It is rapidly 
absorbed and is detectable in the plasma within 2 - 5 min for the nasal spray formulation and 
within 15 min for the oral formulations. Zolmitriptan reaches peak plasma levels in 2 - 4 h and 
significant plasma levels are maintained for up to 6 h and lower levels for over 15 h. As 
zolmitriptan's metabolism is predominantly hepatic, patients with severe hepatic impairment 
should not receive zolmitriptan. However, only 25% of zolmitriptan is bound to plasma proteins 
and thus it is unlikely for drug interactions involving the displacement of highly protein-bound 
drugs. Zolmitriptan is generally very well tolerated and less than half of patients in clinical trials 
have reported adverse events, most of which are mild and transient, although rare serious 
cardiovascular events have been reported with all triptans. When patients are appropriately 
selected, zolmitriptan is both a safe and effective acute care migraine treatment. In this review 
the biological role of serotonin and its receptors is covered, followed by an in-depth review of 
the pharmacodynamics, pharmacokinetics and efficacy of zolmitriptan. Finally, the clinical 
application of zolmitriptan's use in patients is dicussed. 
 
Sternieri et.al (34) Recent progress in the treatment of primary headaches has made 
available specific, effective and safe medications for these disorders, which are widely spread 
among the general population. One of the negative consequences of this undoubtedly positive 
progress is the risk of drug-drug interactions. This review is the first in a two-part series on 
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pharmacokinetic drug-drug interactions of headache medications. Part I addresses acute 
treatments. Part II focuses on prophylactic treatments. The overall aim of this series is to increase 
the awareness of physicians, either primary care providers or specialists, regarding this topic. 
Pharmacokinetic drug-drug interactions of major severity involving acute medications are a 
minority among those reported in literature. The main drug combinations to avoid are: i) 
NSAIDs plus drugs with a narrow therapeutic range (i.e., digoxin, methotrexate, etc.); ii) 
sumatriptan, rizatriptan or zolmitriptan plus monoamine oxidase inhibitors; iii) substrates and 
inhibitors of CYP2D6 (i.e., chlorpromazine, metoclopramide, etc.) and -3A4 (i.e., ergot 
derivatives, eletriptan, etc.), as well as other substrates or inhibitors of the same CYP 
isoenzymes. The risk of having clinically significant pharmacokinetic drug-drug interactions 
seems to be limited in patients with low frequency headaches, but could be higher in chronic 
headache sufferers with medication overuse. 
 
Dowson et.al  (35) As part of an optimal strategy for the management of migraine, the 
individual needs and preferences of patients need to be considered when of patients need to be 
considered when prescribing treatments. Zolmitriptan has been available as a conventional oral 
tablet for more than seven years, and is established as a highly effective, well-tolerated 
compound for the acute treatment of migraine. A bioequivalent, orally disintegrating tablet 
(ODT) of zolmitriptan, which dissolves on the tongue without the need for additional fluid 
intake, has been developed. In a study designed to compare patient preference for zolmitriptan 
ODT and conventional oral sumatriptan tablets, > 60% of the 186 patients questioned had an 
overall preference for zolmitriptan ODT, with > 80% of patients reporting that this was the more 
convenient and less disruptive therapy to take. Approximately 90% of patients agreed that, 
unlike a conventional tablet, zolmitriptan ODT can be taken wherever and whenever a migraine 
occurs. When patient preference for zolmitriptan ODT and the ODT formulation of rizatriptan 
was compared in 171 migraineurs, 70% had an overall preference for zolmitriptan ODT to be 
superior to rizatriptan ODT with respect to taste and aftertaste, as well as packaging. In 
summary, not only is zolmitriptan ODT a convenient tablets, such as the sumatriptan oral tablet, 
but patients generally consider it to be a more attractive option for the acute treatment of 
migraine than the orally disintegrating version of rizatriptan. 
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Tepper et.al (36) The triptans are 5-HT(1B/1D) agonists used as migraine and cluster-
specific agents. Seven are in commercial use worldwide; in order of release these are 
sumatriptan, zolmitriptan, rizatriptan, naratriptan, almotriptan, frovatriptan and eletriptan. 
Sumatriptan has been in clinical use since 1991, and although postmarketing studies have 
stimulated much debate of triptan strengths and weaknesses, their overall safety profile appears 
excellent. The most serious adverse events are cardiovascular, due to coronary artery narrowing 
as a consequence of coronary artery 5-HT(1B) receptor activity. Triptans are contraindicated in 
patients with vascular disease. Other events are even more rare, and include the potential for 
drug-drug interactions, based on metabolic elimination pathways. Serotonin syndrome has been a 
concern, but one large prospective study failed to document a single case, and reports are 
sporadic and not clearly causative. 
 
Villalón et.al (37) Migraine treatment has evolved into the scientific arena, but it seems 
still controversial whether migraine is primarily a vascular or a neurological dysfunction. 
Irrespective of this controversy, the levels of serotonin (5-hydroxytryptamine; 5-HT), a 
vasoconstrictor and a central neurotransmitter, seem to decrease during migraine (with associated 
carotid vasodilatation) whereas an i.v. infusion of 5-HT can abort migraine. In fact, 5-HT as well 
as ergotamine, dihydroergotamine and other antimigraine agents invariably produce 
vasoconstriction in the external carotid circulation. The last decade has witnessed the advent of 
sumatriptan and second generation triptans (e.g. zolmitriptan, rizatriptan, naratriptan), which 
belong to a new class of drugs, the 5-HT1B/1D/1F receptor agonists. Compared to sumatriptan, 
the second-generation triptans have a higher oral bioavailability and longer plasma half-life. In 
line with the vascular and neurogenic theories of migraine, all triptans produce selective carotid 
vasoconstriction (via 5-HT1B receptors) and presynaptic inhibition of the trigeminovascular 
inflammatory responses implicated in migraine (via 5-HT1D/5-ht1F receptors). Moreover, 
selective agonists at 5-HT1D (PNU-142633) and 5-ht1F (LY344864) receptors inhibit the 
trigeminovascular system without producing vasoconstriction. Nevertheless, PNU-142633 
proved to be ineffective in the acute treatment of migraine, whilst LY344864 did show some 
efficacy when used in doses which interact with 5-HT1B receptors. Finally, although the triptans 
are effective antimigraine agents producing selective cranial vasoconstriction, efforts are being 
made to develop other effective antimigraine alternatives acting via the direct blockade of 
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vasodilator mechanisms (e.g. antagonists at CGRP receptors, antagonists at 5-HT7 receptors, 
inhibitors of nitric oxide biosynthesis, etc). These alternatives will hopefully lead to fewer side 
effects. 
 
Dowson et.al (38) Preclinical studies have shown that zolmitriptan is a selective serotonin 
5-HT(1B/1D) receptor agonist (triptan). Randomised, placebo-controlled, double-blind trials in 
patients with migraine have shown that zolmitriptan has good efficacy measured using 2 h 
response and pain-free rates. Migraine-associated symptoms, including nausea, photophobia and 
phonophobia, are also improved with zolmitriptan. Oral zolmitriptan (2.5 and 5 mg) has an onset 
of action within 45 min and efficacy is sustained in most patients who respond at 2 h. The orally-
disintegrating zolmitriptan tablet has the advantage that it may be taken immediately, without the 
need for additional fluids, any time a migraine headache occurs. Patients may benefit in terms of 
improved efficacy from the convenience of the disintegrating tablet, since there is evidence that 
taking triptan therapy as early as possible in an attack is advantageous. For similar reasons, as 
well as improved efficacy, a nasal spray formulation is in development. Zolmitriptan is effective 
in the treatment of migraine associated with menses and migraine with aura. There is no 
tachyphylaxis following repeated doses for multiple attacks of migraine over a prolonged period 
of time. Compared to placebo, the incidence of persistent migraine headache is reduced by 
zolmitriptan and recurrent migraine headache occurs less frequently. Zolmitriptan has also 
shown efficacy in the treatment of persistent and/or recurrent migraine headache. Comparative 
clinical studies have shown overall that zolmitriptan has similar or superior efficacy to 
sumatriptan in the treatment of migraine. Specifically, zolmitriptan 2.5 mg was significantly 
more effective than sumatriptan 25 or 50 mg according to a number of end points, including 
headache response at 2 h. Oral zolmitriptan is also effective in the acute treatment of cluster 
headache. Zolmitriptan is generally well tolerated, with most adverse events being mild-to-
moderate, transient and resolving without intervention or the need for treatment withdrawal. The 
consistent efficacy in treating all types of migraine and the choice of available formulations 
make zolmitriptan acceptable to patients and a suitable first-line therapy for the treatment of 
migraine. 
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Adelman et.al (39) Triptans, beginning with sumatriptan, have revolutionized the 
treatment of migraine. New triptans in several formulations will soon become available in the 
United States. Although the similarities of these 5-hydroxytryptamine (5-HT) 1B/1D receptor 
agonists outweigh their differences, important differences in pharmacokinetics and clinical 
responses do exist. Subcutaneous sumatriptan has the most rapid onset of action and greatest 
efficacy but the most adverse effects. Intranasal sumatriptan also has rapid onset of action, but at 
2 hours its efficacy is comparable to that of oral zolmitriptan. Of the oral triptans, rizatriptan 
seems to have the greatest early efficacy. Both rizatriptan and zolmitriptan are now available as 
rapidly dissolving wafers. Almotriptan, the newest of the triptans, has a response rate similar to 
that of oral sumatriptan and may produce fewer adverse effects. Naratriptan and frovatriptan, 
with their slow onset, high tolerability, and long half-lives, may have a role in aborting 
prolonged migraine attacks and in headache prevention. Eletriptan at higher doses (80 mg) has a 
response rate approaching that of rizatriptan but may be limited by potential side effects. The 
many triptans available offer the opportunity to individualize migraine treatment, depending on 
the patient's attack characteristics, tolerance, and preferences. 
Tfelt-Hansen et.al (40) Triptans are a new class of compounds developed for the 
treatment of migraine attacks. The first of the class, sumatriptan, and the newer triptans 
(zolmitriptan, naratriptan, rizatriptan, eletriptan, almotriptan and frovatriptan) display high 
agonist activity at mainly the serotonin 5-HT1B and 5-HT1D receptor subtypes. As expected for 
a class of compounds developed for affinity at a specific receptor, there are minor 
pharmacodynamic differences between the triptans. Sumatriptan has a low oral bioavailability 
(14%) and all the newer triptans have an improved oral bioavailability and for one, risatriptan, 
the rate of absorption is faster. The half-lives of naratriptan, eletriptan and, in particular, 
frovatriptan (26 to 30h) are longer than that of sumatriptan (2h). These pharmacokinetic 
improvements of the newer triptans so far seem to have only resulted in minor differences in 
their efficacy in migraine. Double-blind, randomised clinical trials (RCTs) comparing the 
different triptans and triptans with other medication should ideally be the basis for judging their 
place in migraine therapy. In only 15 of the 83 reported RCTs were 2 triptans compared, and in 
11 trials triptans were compared with other drugs. Therefore, in all placebo-controlled 
randomised clinical trials, the relative efficacy of the triptans was also judged by calculating the 
therapeutic gain (i.e. percentage response for active minus percentage response for placebo). The 
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mean therapeutic gain with subcutaneous sumatriptan 6mg (51%) was more than that for all 
other dosage forms of triptans (oral sumatriptan 100mg 32%; oral sumatriptan 50mg 29%: 
intranasal sumatriptan 20mg 30%; rectal sumatriptan 25mg 31%; oral zolmitriptan 2.5mg 32%; 
oral rizatriptan 10mg 37%; oral eletriptan 40mg 37%; oral almotriptan 12.5mg 26%). Compared 
with oral sumatriptan 100mg (32%), the mean therapeutic gain was higher with oral eletriptan 
80mg (42%) but lower with oral naratriptan 2.5mg (22%) or oral frovatriptan 2.5mg (16%). The 
few direct comparative randomised clinical trials with oral triptans reveal the same picture. 
Recurrence of headache within 24 hours after an initial successful response occurs in 30 to 40% 
of sumatriptan-treated patients. Apart from naratriptan, which has a tendency towards less 
recurrence, there appears to be no consistent difference in recurrence rates between the newer 
triptans and sumatriptan. Rizatriptan with its shorter time to maximum concentration (tmax) 
tended to produce a quicker onset of headache relief than sumatriptan and zolmitriptan. The 
place of triptans compared with non-triptan drugs in migraine therapy remains to be established 
and further RCTs are required. 
Egilius L H Spierings et.al (41) Migraine is a common, often disabling, neurovascular 
disease that has been shown to be associated with abnormal serotonergic activity. Drugs that 
modulate serotonin receptors are commonly used in the acute treatment of a migraine attack. 
Zolmitriptan, a 5-hydroxytryptophan1B/1D receptor agonist, is once such drug that is used in acute 
migraine therapy. Zolmitriptan is FDA approved for the treatment of acute migraine attacks and 
there is recent literature demonstrating its efficacy in the acute treatment of cluster attacks. It is 
rapidly absorbed and is detectable in the plasma within 2 – 5 min for the nasal spray formulation 
and within 15 min for the oral formulations. Zolmitriptan reaches peak plasma levels in 2 – 4 h 
and significant plasma levels are maintained for up to 6 h and lower levels for over 15 h. As 
zolmitriptan's metabolism is predominantly hepatic, patients with severe hepatic impairment 
should not receive zolmitriptan. However, only 25% of zolmitriptan is bound to plasma proteins 
and thus it is unlikely for drug interactions involving the displacement of highly protein-bound 
drugs. Zolmitriptan is generally very well tolerated and less than half of patients in clinical trials 
have reported adverse events, most of which are mild and transient, although rare serious 
cardiovascular events have been reported with all triptans. When patients are appropriately 
selected, zolmitriptan is both a safe and effective acute care migraine treatment. In this review 
the biological role of serotonin and its receptors is covered, followed by an in-depth review of 
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the pharmacodynamics, pharmacokinetics and efficacy of zolmitriptan. Finally, the clinical 
application of zolmitriptan's use in patients is dicussed. 
 
Ch. Anil kumar  et.al  (42)  Zolmitriptan is a Selective Serotonin receptor agonist of the 
1B and 1D  subtype.    Used  in  the  acute  treatment  of Migraine attacks  with  or without aura  
and headaches.  The  present  research  work  is  aimed  at developing  a  Formulate  and  
Evaluated  of  an  Oro  dispersible  tablet dosage  form  of  Zolmitriptan.  The  target  of  these  
new  oral dissolving/disintegrating  dosage  forms  have  generally  been  pediatric, geriatric,  
bedridden  and  developmentally  disabled  patients  and  also patients with persistent nausea, 
who are in traveling, or who have little or  no  access  to  water  are  also  good  candidates  for  
ODTs  Direct Compression  method  was  employed  for  blending  of  drug  with polymers in 
the given ratio as a 9 formulations. The prepared powder blends  were  then  compressed  into  
tablets  using  the  necessary Superdisintegrants  (CCS,  CP, and  SSG)  and  Excipients.  The  
tablets  were  evaluated  for  Weight  variation,  thickness,hardness,  friability,  Drug  Content  
and  Disintegrating  Time  (Sec)  were  subjected  to  a  10 minutes  in  vitro  drug  release  
studies  (USP  dissolution  rate  test  apparatus  II,  50  rpm,  370C ±0.50C)  using  phosphate  
buffer,  pH  6.8  as  a  dissolution  medium  (900ml).    The  amount  of Zolmitriptan  released  
from  the  tablet  formulations  at  different  time  intervals  was  estimated using a UV 
spectroscopy method. The formulations that showed a considerable retardation of  the  drug  
release  are  considered  promising. 
 
Andrew J. Dowson et.al (43) A  simple,selective,linear,presice and accurate RP-HPLC 
method was developed and validated for rapid assy of zolmitriptan in tablet dosage 
form.Isocratic solution at a flow rate of 1.0ml/min was eemployed on symmetry 
C18(280*4.6mm,5µm in paticle size) at ambient temperature.the mobile phase consisted of 
0.01%triethyl amine :acetonitrile:0.02M NH4H2PO4 ;28.2:25:46.8(V/V/V).The uv detection 
wavelength was 225nm and 20µl sample was injected,the retention time for zolmitriptan was 
3.705 min.the  percentage RSD for precision and accuracy of themethod was found to be less 
than 2%.the method was validated as per ich guide lines.the method was successfully applied for 
routine analysis of zolmitriptan in tablet dosage form. 
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 Diener HC et.al (44) A simple sensitive and specific reverse phase high performance 
liquid chromatographic method has been developed for the determination of zolmitriptan tablet 
dosage forms.chromatographic separation was achieved on a kromasil C18(150*4.6mm),5.0µm 
column with a 750ml of 0.01 anhydrous dipotassium hydrogen orthophosphate, added 250ml of 
methanol and fixed as a mobile phase ,detection was at 230nm.response was a linear function of 
sconcentration in the range 2-0.01µg/ml for Zolmitriptan, LOD and LOQ for Zolmitriptan was 
found to be 0.01µg/ml and 0.03µg/ml. 
Accuracy (recoveries 90-97%) and reproducibility were found to satisfactory 
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                                            3. AIM AND OBJECTIVE 
 
AIM  
The aim of the present study was to formulate Zolmitriptan oral disintegrating tablets by 
direct compression method and to evaluate the formulations for various parameters to produce 
oral dosage form with better pharmaceutical and therapeutic properties. 
 
OBJECTIVE 
The objective of the present investigation was to prepare Oral disintegrating tablets’s of 
Zolmitriptan and to evaluate the effect of different superdisintegrants on their disintegration time 
and In vitro  dissolution characteristics with increased bioavailability, rapid absorption, effective 
therapy and patient compliance because fast onset of action is desirable in epilepsy without the 
use of water. 
Based on the evaluation parameters, the formulation with better disintegration and dissolution 
profile  when compared to the other formulations. 
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                                                   4. PLAN OF WORK 
The study was proposed to carry out in the following: 
A.1.Formulaion ad evaluation of Oral Disintegrantion tablets of Zolmitriptan by using    
Superdisintegrants (Crosscarmellose Sodium, Sodium Starch Glycolate and Crosspovidone) 
in different concentrations by using direct compression method. 
B. Pre compression studies: 
1 .FTIR 
2. Angle of repose 
3. Bulk density 
4. Tapped density 
5. Compressibility index 
C. Formulation of tablets 
D. Post compression studies: 
1. Tablet thickness 
2. Weight variation 
3. Hardness 
4. Friability 
5 .Disintegration test 
6. Dissolution test. 
 7. Drug content estimation  
E. kinetic release studies 
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5. PROFILES 
 
ZOLMITRIPTAN (45) 
 
Drug Name   :  Zolmitriptan 
 
Category : Serotonin receptor agonist  used in the acute treatment of 
 migraine attacks  
 
Empirical formulae :  C16H21N3O2 
 
Molecular weight    :   287.36 
 
Solubility     :  it is soluble in water and methanol and HCL 
 
Pharmacokinetic data:- 
 
Bioavailability    :  40% oral  
  
Protien binding   :  25% 
 
Metabolism      :  Hepatic (CYP1A2-mediated, to active metabolite) 
 
Half life     :  3 hours 
 
Excretion     : Renal (65%) and fecal (35%) 
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Chemical structure    : 
                                            
 
 
Chemical name: 
 
(S)-4-({3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}methyl)-1,3-oxazolidin-2-one 
 
 
Mechanism of action 
 
Zolmitriptan binds with high affinity to human recombinant 5-HT1D and 5-HT1B 
receptors. It exhibits modest affinity for 5-HT1A  receptors, but has no significant affinity (as 
measured by radio ligand binding assays) or pharmacological activity at 5-HT2 , 5-HT3 , 5-HT4 
, alpha1- , alpha2- , or beta1-  adrenergic; H1 , H2 , histaminic; muscarinic; dopamine1 , or 
dopamine 2 receptors. The N-desmethyl metabolite also has high affinity for 5-HT1B/1D and 
modest affinity for 5-HT1A receptors. Current theories proposed to explain the etiology of 
migraine headache suggest that symptoms are due to local cranial vasodilatation and/or to the 
release of sensory neuropeptides (vasoactive intestinal peptide, substance P and calcitonin gene-
related peptide) through nerve endings in the trigeminal system. The therapeutic activity of 
zolmitriptan for the treatment of migraine headache can most likely be attributed to the agonist 
effects at the 5-HT 1B/1D receptors on intracranial blood vessels (including the arterio-venous 
anastomoses) and sensory nerves of the trigeminal system which result in cranial vessel 
constriction and inhibition of pro-inflammatory neuropeptide release. 
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CLINICAL PHARMACOKINETIC AND BIOAVAILABILITY 
 
Absorption 
 
   Zolmitriptan is well absorbed after oral administration for both the conventional tablets 
and the orally disintegrating tablets. Zolmitriptan displays linear kinetics over the dose range of 
2.5 to 50 mg. The AUC and C of zolmitriptan are similar following administration of ZOMIG 
Tablets and ZOMIGZMT Orally Disintegrating Tablets, but the T is somewhat later with 
ZOMIG-ZMT, with a median T of 3 hours for the orally disintegrating tablet compared with 1.5 
hours for the conventional tablet. The AUC, Cmax
 
, and Tmax
 
for the active N-desmethyl 
metabolite are similar for the two formulations. During a moderate to severe migraine attack, 
mean AUC and C for zolmitriptan, dosed as a conventional tablet, were decreased by 40% and 
25%, respectively, and mean T was delayed by one half hour compared to the same patients 
during a migraine free period. Food has no significant effect on the bioavailability of 
zolmitriptan. No accumulation occurred on multiple dosing. 
 
 Distribution 
                     
 Mean absolute bioavailability is approximately 40-50%. The mean apparent volume of 
distribution is 7.0 L/kg. Plasma protein binding of zolmitriptan is 25% over the concentration 
range of 10- 1000ng/mL. 
 
 Metabolism 
                   
Zolmitriptan is converted to an active N-desmethyl metabolite such that the metabolite 
concentrations are about two-thirds that of zolmitriptan. Because the 5HT potency of the 
metabolite is 2 to 6 times that of the parent, the metabolite may contribute a substantial portion 
of the overall effect after zolmitriptan administration. 
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Elimination 
 
Total radioactivity recovered in urine and feces was 65% and 30% of the administered 
dose, respectively. About 8% of the dose was recovered in the urine as unchanged zolmitriptan. 
Indole acetic acid metabolite accounted for 31% of the dose, followed by N-oxide (7%) and N-
desmethyl (4%) metabolites. The indole acetic acid and N-oxide metabolites are inactive. Mean 
total plasma clearance is 31.5mL/min/kg, of which one-sixth is renal clearance. The renal 
clearance is greater than the glomerular filtration rate suggesting renal tubular secretion. 
 
                                            
                                                    POLYMER PROFILE 
 
CROSCARMELLOSE SODIUM (46) 
 
Nonproprietary Name:                                                 
BP  :  Croscarmellose Sodium 
JP  :  Croscarmellose Sodium 
PhEur  :  Croscarmellose Sodium 
USP-NF :  CroscarmelloseSodium 
 
Synonym    
 
Ac-Di-Sol; Carmellosum Natricum Conexum, Crosslinked Carboxy methyl cellulose 
Sodium, Explocel, Modified cellulose gum, Nymcel ZSX, Pharmacel XL, Primellose, 
Solutab,Vivasol. 
 
Chemical name 
 
Cellulose, carboxymethyl ether, sodium salt, cross linked. 
 
Empirical formula  : C8H16O8 
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Molecular weight  : 240.20784  
 
Structural formula  :  
 
 
 
 
 
     
 
       
        
 
 
Functional category  : Tablet and capsule disintegrant. 
 
Applications in pharmaceutical formulation and technology 
 
 Croscarmellose sodium is used in oral pharmaceutical formulations as a disintegrant for 
capsules , tablets, and granules. In tablet formulations, Croscarmellose sodium may be used in 
both direct-compression and wet-granulation processes. When used in wet granulations, the 
Croscarmellose sodium should be added in both the wet and dry stages of the process (intra- and 
extragranularly) so that the wicking and swelling ability of the disintegrant is best 
utilized.(Croscarmellose sodium at concentrations up to 5% w/w may be used as a tablet 
disintegrant, although normally 2% w/w is used in tablets prepared by direct compression and 
3% w/w in tablets prepared by a wet-granulation process. 
 
 
 
 
33 
 
 
Description  
   
Croscarmellose sodium occurs as an odorless, white or grayish white  powder. 
 
Density (true)  : 1.543 g/cm3  for Ac-Di-Sol 
 
 
Solubility 
 
Insoluble in water, although  Croscarmellose sodium rapidly swells to 4–8 times its 
original volume on contact with water. Practically insoluble in acetone, ethanol and toluene. 
 
Incompatibilities 
 
The efficacy of disintegrants, such as Croscarmellose sodium, may be slightly reduced in 
tablet formulations prepared by either the wet-granulation or direct-compression process that 
contain hygroscopic excipients such as sorbitol. Croscarmellose sodium is not compatible with 
strong acids or with soluble salts of iron and some other metals such as aluminum, mercury, and 
zinc. 
 
Stability and storage conditions 
 
 Croscarmellose sodium is a stable though hygroscopic material. A model tablet 
formulation prepared by direct compression, with croscarmellose sodium as a disintegrant, 
showed no significant difference in drug dissolution after storage at 308C for 14 months. 
Croscarmellose sodium should be stored in a well-closed container in a cool, dry place. 
 
                              
                            
                               
34 
 
SODIUM STARCH GLYCOLATE (46) 
 
Nonproprietary Name  
 
BP  : Sodium Starch Glycolate 
PhEur  : Sodium Starch Glycolate 
USP-NF : Sodium Starch Glycolate 
 
Synonyms 
  
Carboxymethyl starch, sodium salt carboxymethylamylum natricum, Explosol, Explotab, 
Glycolys,Primojel, starch carboxymethyl ether, sodium salt,Tablo; Vivastar P. 
 
Chemical name   : Sodium carboxymethyl starch. 
 
Empirical formula   : C24H44O6Na 
 
Molecular weight       : 222.25. 
 
Structural formula 
 
                                        
 
 
Functional category  : Tablet and capsule disintegrant. 
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 Applications in pharmaceutical formulation and technology 
 
• Sodium starch glycolate is widely used in oral pharmaceuticals as a disintegrant in capsule and 
tablet formulations. 
• It is commonly used in tablets prepared by either direct-compression or wet-granulation 
processes. The usual concentration employed in a formulation is between 2% and 8%, with the 
optimum concentration about 4%, although in many cases 2% is sufficient. Disintegration occurs 
by rapid uptake of water followed by rapid and enormous swelling. Although the effectiveness of 
many disintegrants is affected by the presence of hydrophobic excipients such as lubricants, the 
disintegrant efficiency of sodium starch glycolate is unimpaired. Increasing the tablet 
compression pressure also appears to have no effect on disintegration time. 
• Sodium starch glycolate has also been  investigated for use as a suspending vehicle. 
 
Description 
 
 Sodium starch glycolate is a white or almost white free-flowing very hygroscopic powder. 
The PhEur 6.0 states that when examined under a microscope it is seen to consist of: granules, 
irregularly shaped, ovoid or pear-shaped, 30–100 mm in size, or rounded, 10–35 mm in size; 
compound granules consisting of 2–4 components occur occasionally; the granules have an 
eccentric hilum and clearly visible concentric striations. Between crossed nicol prisms, the 
granules show a distinct black cross intersecting at the hilum; small crystals are visible at the 
surface of the granules. The granules show considerable swelling in contact with water. 
 
Density(true)           : 1.56 g/cm3 for Primojel; 
                                  1.49 g/cm3 for Tablo. 
 
Melting point           :  Does not melt, but chars at approximately 200C. 
 
Solubility          : Practically insoluble in methylene chloride. It gives a  translucent     
suspension in water. 
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Incompatibilities       : Sodium starch glycolate is incompatible with ascorbic acid. 
 
Stability and storage conditions 
 
                       Tablets prepared with sodium starch glycolate have good storage properties. 
Sodium starch glycolate is stable although very hygroscopic, and should be stored in a well-
closed container in order to protect it from wide variations of humidity and temperature, which 
may cause caking. The physical properties of sodium starch glycolate remain unchanged for up 
to 3 years if it is stored at moderate temperatures and humidity. 
                                      
                                          CROSSPOVIDONE (46) 
 
Nonproprietary Names:    
 
BP : Crospovidone                                       
PhEur  : Crospovidone 
USP-NF : Crospovidone 
 
Synonyms 
                 
Crospovidonum,  Crospopharm,  crosslinked povidone;, E1202, Kollidon CL; Kollidon 
CL-M, Polyplasdone XL, Polyplasdone XL-10, polyvinylpolypyrrolidon,; PVPP, 1-vinyl-2-
pyrrolidinone homopolymer. 
 
 Chemical Name :   1-Ethenyl-2-pyrrolidinone homopolymer  
 
  Empirical formula : (C6H9No)n 
 
  Molecular weight : >1 000 000 
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The usp32–nf27 describes crospovidone as a water-insoluble synthetic crosslinked 
shomopolymer of n-vinyl-2-pyrrolidinone. An exact determination of the molecular weight   has 
not been established because of the insolubility of the material. 
 
  Structural formula 
 
                      
 
 
Functional category  : Tablet disintegrant. 
 
Applications in pharmaceutical formulations and technology 
                        
• Crospovidone is a water-insoluble tablet disintegrant and dissolution agent used at 2–5%  
concentration in tablets prepared by direct compression or wet- and dry-granulation methods. It 
rapidly exhibits high capillary activity and pronounced hydration capacity, with little tendency to 
form gels. Studies suggest that the particle size of crospovidone strongly influences 
disintegration of analgesic tablets. Larger particles provide a faster disintegration than smaller 
particles. 
• Crospovidone can also be used as a solubility enhancer. With the technique of co-evaporation. 
• crospovidone can be used to enhance the solubility of poorly soluble drugs. The drug is  
adsorbed on to crospovidone in the presence of a suitable solvent and the solvent is then 
evaporated. This technique results in faster dissolution rate. 
   
 
 
 
38 
 
   Description 
                        
  Crospovidone is a white to creamy-white, finely divided, freeflowing, practically 
tasteless, odorless or nearly odorless, hygroscopic powder. 
 
  Density   :   1.22 g/cm3 
 
   Incompatabilities  
         
                           Crospovidone is compatible with most organic and inorganic pharmaceutical 
ingredients. When exposed to a high water level, crospovidone may form molecular adducts with 
some materials. 
 
Stability and storage conditions: 
 
                          Since crospovidone is hygroscopic, it should be stored in an airtight container in 
a cool, dry place.  
   
                                           EXCEPIENT PROFILE 
 
SUCRALOSE (47) 
 
Nonproprietary Name : USP-NF: Sucralose 
 
Synonyms: 
                       Splenda; sucralosa; sucralosum; SucraPlus; TGS;  
                      10,40,60-trichlorogalactosucrose; 4,10,60     
                       Trichloro-4,10,60-trideoxy-galacto-sucrose.  
 
Chemical Name  : 1,6-Dichloro-1,6-dideoxy-b-D-fructofuranosyl-              
                                       4-chloro-4-deoxya- D-galactopyranoside  
  Empirical formula   
                                              
 Molecular weight   
 
 Structural formula     
 
                                
 
 
 Functional category 
 
 Applications in pharmaceutical formulation and technology
 
Sucralose is used as a sweetening agent in beverages, foods, and 
applications. It has a sweetening power approximately 300
no aftertaste. It has no nutritional value, is noncariogenic, does not promote dental caries, and 
produces no glycemic response. 
 
  Description 
 
  Sucralose is a white to off-white colored, free
 
  Density (true) : 1.63 g/cm3
   
  Melting point : 1308C (for anhydrous crystalline form); 36.58C (for pentahydrate).
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:  C12 H19 C13O8   
:  397.64 
                    
:  Sweetening agent. 
 
–1000 times that of sucrose and has 
-flowing, crystalline powder. 
 
pharmaceutical 
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 Stability and Storage Conditions: 
                       
   Sucralose is a relatively stable material. In aqueous solution, at highly acidic conditions 
(pH < 3), and at high temperatures (4358C), it is hydrolyzed to a limited extent, producing 4-
chloro-4- deoxygalactose and 1,6-dichloro-1,6-dideoxyfructose. In food products, sucralose 
remains stable throughout extended storage periods, even at low pH. However, it is most stable 
at pH 5–6. Sucralose should be stored in a well-closed container in a cool, dry place, at a 
temperature not exceeding 218C. Sucralose, when heated at elevated temperatures, may break 
down with the release of carbon dioxide, carbon monoxide, and minor amounts of hydrogen 
chloride. 
 
                                  MAGNESIUM STEARATE (47) 
 
Nonproprietary names: 
           
   BP  : Magnesium Stearate 
             JP  : Magnesium Stearate 
             PhEur : Magnesium Stearate 
       USP-NF : Magnesium Stearate 
 
Synonyms 
                      Dibasic magnesium stearate; magnesium distearate; magnesiistearas; magnesium 
octadecanoate; octadecanoic acid, magnesiumsalt; stearic acid, magnesium salt; Synpro 90. 
 
Chemical Name : Octadecanoic acid magnesium salt 
 
Emperical formula : C36H70MgO4  
 
Molecular weight : 591.24 
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The USP32–NF27 describes magnesium stearate as a compound of magnesium with a mixture of 
solid organic acids that consists chiefly of variable proportions of magnesium stearate and 
magnesium palmitate (C32H62MgO4). The PhEur 6.5 describes magnesium stearate as a 
mixture of solid organic acids consisting mainly of variable proportions of magnesium stearate 
and magnesium palmitate obtained from sources of vegetable or animal. 
 
Structural formula 
 
                                   
 
Functional category  : Tablet and capsule lubricant 
 
Applications in pharmaceutical formulation and technology 
                             
 Magnesium stearate is widely used in cosmetics, foods, and pharmaceutical formulations. It is 
primarily used as a lubricant incapsule and tablet manufacture at concentrations between 
0.25%and 5.0% w/w. It is also used in barrier creams. 
   
Description 
 
Magnesium stearate is a very fine, light white, precipitated or milled, impalpable powder 
of low bulk density, having a faint odor stearic acid and a characteristic taste. The powder is 
greasy to the touch and readily adheres to the skin.  
 
 Density (true) :  1.092 g/cm3 
 
Melting range : 117–1508C 
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Solubility:  Practically insoluble in ethanol, ethanol (95%), ether and water; slightly soluble in 
warm benzene and warm ethanol (95%). 
 
Incompatabilities 
 
 Incompatible with strong acids, alkalis, and iron salts. Avoid mixing with strong 
oxidizing materials. Magnesium stearate cannot be used in products containing aspirin, some 
vitamins, and most alkaloidal salts. 
 
  Safety 
 
      Magnesium stearate is widely used as a pharmaceutical excipients and is generally    
regarded as being nontoxic following oral administration. However, oral consumption of large 
quantities may produce a laxative effect or mucosal irritation. No toxicity information is 
available relating to normal routes of occupational exposure. Limits for heavy metals in 
magnesium stearate have been evaluated in terms of magnesium stearate worst case daily intake 
and heavy metal composition. Toxicity assessments of magnesium stearate in rats have indicated 
that it is not irritating to the skin, and is nontoxic when administered orally or inhaled. 
Magnesium stearate has not been shown to be carcinogenic when implanted into the bladder of 
mice 
 
   Stability and storage conditions 
                       
     Magnesium stearate is stable and should be stored in a well-closed container in a cool, 
dry place. 
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                                                      MANNITOL (46) 
 
Nonproprietary names    
 BP         :  Mannitol 
                                 JP          : D-Mannitol 
                                 PhEur     : Mannitol 
                                 USP       : Mannitol 
 
 
Synonyms          :         Cordycepic acid, C*PharmMannidex, E421, 
          Emprove,manna sugar; D-mannite;  
          mannite, mannitolum, Mannogem, Pearlitol. 
 
Chemical formula       :  D-Mannitol. 
 
Empirical formula     :  C6H14O6 
 
Molecular weight      :  182.17 
 
Chemical structure 
 
                                      
 
Functional category 
 
 Diluent; plasticizer, sweetening agent, tablet and capsule diluents, therapeutic agent, 
tonicity agent 
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Applications in pharmaceutical formulation and technology:  
                       
• Mannitol is widely used in pharmaceutical  formulations and food products. In pharmaceutical 
preparations it is primarily used as a diluent (10–90% w/w) in tablet formulations, where it is of 
particular value since it is not hygroscopic and may thus be used with moisture-sensitive active 
ingredients. 
• Mannitol may be used in direct-compression tablet applications, For which the granular and 
spray-dried forms are available,or in wet granulations. Granulations containing mannitol have 
the advantage of being dried easily. Specific tablet applications include antacid preparations, 
glyceryl trinitrate tablets, and vitamin preparations.  
• Mannitol is commonly used as an excipient in the manufacture of chewable tablet formulations 
because of its negative heat of solution, sweetness, and ‘mouth Feel’. In lyophilized preparations, 
mannitol (20–90% w/w) has been included as a carrier to produce a stiff, homogeneous cake that 
improves the appearance of the lyophilized plug in a vial. A pyrogen-free form is available 
specifically for this use. 
• Mannitol has also been used to prevent thickening in aqueous antacid suspensions of aluminum 
hydroxide (<7% w/v). It has been suggested as a plasticizer in  soft-gelatin capsules, as a 
component of sustained-release tablet formulations,and as a carrier in dry powder inhalers.It is 
also used as a diluent in rapidly dispersing oral dosage forms. 
• It is used in food applications as a bulking agent. Therapeutically, mannitol administered 
parenterally is used as an osmotic diuretic, as a diagnostic agent for kidney function, as an 
adjunct in the treatment of acute renal failure, and as an agent to reduce intracranial pressure, 
treat cerebral edema, and reduce intraocular pressure. Given orally, mannitol is not absorbed 
significantly from the gastrointestinal tract, but in large doses it can cause osmotic diarrhea. 
 
Description 
   
    Mannitol is D-mannitol. It is a hexahydric alcohol related to mannose and is isomeric 
with sorbitol. Mannitol occurs as a white, odorless, crystalline powder, or freeflowing granules. 
It has a sweet taste, approximately as sweet as glucose and half as sweet as sucrose, and imparts 
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a cooling sensation in the mouth. Microscopically, it appears as orthorhombic needles when 
crystallized from alcohol. Mannitol shows polymorphism. 
 
Density (true) : 1.514 g/cm3 
 
   Incompatabilities 
                         
      Mannitol solutions, 20% w/v or stronger, may be salted out by potassium chloride or 
sodium chloride.(19) Precipitation has been reported to occur when a 25% w/v mannitol solution 
was allowed to contact plastic. Sodium cephapirin at 2 mg/mL and 30 mg/mL concentration is 
incompatible with 20% w/v aqueous mannitol solution. Mannitol is incompatible with xylitol 
infusion and may form complexes with some metals such as aluminum, copper, and iron. 
Reducing sugar impurities in mannitol have been implicated in the oxidative degradation of a 
peptide in a lyophilized formation. Mannitol was found to reduce the oral bioavailability of 
cimetidine compared to sucrose. 
 
 Stability and storage conditions: 
   
  Mannitol is stable in the dry state and in aqueous solutions. Solutions may be sterilized 
by filtration or by autoclaving and if necessary may be autoclaved repeatedly with no adverse 
physical or chemical effects. In solution, mannitol is not attacked by cold, dilute acids or alkalis, 
nor by atmospheric oxygen in the absence of catalysts. Mannitol does not undergo Millard 
reactions. The bulk material should be stored in a well-closed container in a cool, dry place. 
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COLLOIDAL SILICON DIOXIDE (46) 
 
Nonproprietary names:   
 BP  : Colloidal Anhydrous Silica 
             JP  : Light Anhydrous Silicic Acid 
              PhEur  : Silica, Colloidal Anhydrous 
             USP-NF : Colloidal Silicon Dioxide 
 
Synonyms 
 
Aerosil; Cab-O-Sil; Cab-O-Sil M-5P; colloidal silica; fumed silica fumed silicon dioxide; 
hochdisperses silicum dioxide, SAS,silica colloidalis anhydrica; silica sol; silicic anhydride, 
Silicon dioxide colloidal, silicon dioxide fumed, synthetic amorphous silica, Wacker HDK. 
 
 Chemical name  : Silica  
 
 Empirical formula  : SiO2  
 
Molecular weight  : 60.08 
 
 Structural formula: 
                                              
Functional category 
 
Adsorbent, anti caking agent, Emulsion stabilizer, glident, suspending agent,tablet 
disintegrant, Thermal stabilizer, viscosity-increasing agent. 
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Applications in pharmaceutical formulation and technology 
 
• Colloidal silicon dioxide is widely used in pharmaceuticals,Cosmetics and food products. Its 
small particle size and large specific surface area give it desirable flow characteristics that are 
exploited to improve the flow properties of dry powders in a number of processes such as 
tableting and capsule filling.  
• Colloidal silicon dioxide is also used to stabilize emulsions and as a thixotropic thickening and 
suspending agent in gels and semisolid preparations. Colloidal silicon dioxide is used to promote 
particulate suspension, eliminate hard settling, and minimize the clogging of spray nozzles. 
• Colloidal silicon dioxide is also used as a tablet disintegrant and as an adsorbent dispersing agent 
for liquids in powders. 
• Colloidal silicon dioxide is frequently added to suppository formulations containing lipophilic 
excipients to increase viscosity, prevent sedimentation during molding, and decrease the release 
rate. 
• Colloidal silicon dioxide is also used as an adsorbent during the preparation of wax 
microspheres,as a thickening agent for topical preparations,and has been used to aid the freeze-
drying of nanocapsules and nanosphere suspensions. 
 
Description 
 
 Colloidal silicon dioxide is a submicroscopic fumed silica with a particle size of about 
15 nm. It is a light, loose, bluish-white-colored,odorless, tasteless, amorphous powder. 
 
Density(bulk)  : 0.029–0.042 g/cm3 
 
Melting point  : 16008C 
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Solubility 
 
 Practically insoluble in organic solvents, water, and acids, except hydrofluoric acid; 
soluble in hot solutions of alkali hydroxide. Forms a colloidal dispersion with water. For Aerosil, 
solubility in water is 150 mg/L at 258C (pH 7). 
 
Specific gravity : 2.2 
 
Incompatabilities  : Incompatible with diethylstilbestrol preparations. 
 
Safety 
   
Colloidal silicon dioxide is widely used in oral and topical pharmaceutical products and 
is generally regarded as an essentially nontoxic and nonirritant excipient. However, 
intraperitoneal and subcutaneous injection may produce local tissue reactions and/or granulomas. 
Colloidal silicon dioxide should therefore not be administered parenterally. 
 
Stability and storage conditions 
 
 Colloidal silicon dioxide is hygroscopic but adsorbs large quantities of water without 
liquefying. When used in aqueous systems at a pH  0–7.5, colloidal silicon dioxide is effective in 
increasing the viscosity of a system. However, at a pH greater than 7.5 the viscosity increasing 
properties of colloidal silicon dioxide are reduced; and at a pH greater than 10.7 this ability is 
lost entirely since the silicon dioxide dissolves to form silicates.Colloidal silicon dioxide powder 
should be stored in a well-closed container. 
 
                                                     
 
 
 
 
                                                             
 
Excipient Name  : citric acid
 
Category 
 
 Citric acid is a weak organic acid
preservative/conservative and is also used to add
 
Molecular weight  :  192.12352
 
Emperical formula  : C6H8O7 
 
Chemical structure  :  Citric acid
  IUPAC Name   : 2
 
   Solubility   : Very
                        Soluble
 
 Anti coagulants   : Agents that prevent clotting.
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CITRIC ACID (48): 
 
 with the formula C6H8O7. It is a natural 
 an acidic or sour taste to foods and drinks.
  
 
 
 
-hydroxypropane-1,2,3-tricarboxylic acid 
 soluble in ethanol49 
 in ether, ethyl acetate, insoluble in benzene,
 
 
 
 chloroform 
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 Chelating agents 
 
                     Chemicals  that  bind to  and  remove ions from solutions. Many chelating agents 
function through the formation of   coordination complexes with metals. 
 
Description :  citric acid is a white crystalline powder. 
 
Odour  : Odorless 
 
  BIO MEDICAL EFFECTS AND TOXICITY: 
 
   Absorption, distribution, and metabolism 
 
                        A portion  of the circulating (mainly metabolic but also ingested) citric acid is 
excreted in urine, with 24-hour urine reference values between 1.5 and 3.68 mmol, 
corresponding to 0.29-0.71 g citric acid excreted per person per day. 
 
Metabolism/ matebolites 
 
              Citric acid is a normal metabolite and an intermediate in cellular oxidative metabolism 
... The acid is formed in the mitochondrion after condensation of acetate with oxaloacetate. The 
six-carbon acid is then successively degraded to a series of four-carbon acids, effectively 
accomplishing oxidation of acetate in the cell. 
   In human (as well as in animal and plant) physiology, citric acid is a very common intermediate 
in one of the central biochemical cycles, the Krebs or tricarboxylic acid cycle, which takes place 
in every cell. It completes the breakdown of pyruvate formed from glucose through glycolysis, 
thereby liberating carbon dioxide and a further four hydrogen atoms which are picked up by 
electron transport molecules. Thus, in man approximately 2 kg of citric acid are formed and 
metabolised every day. This physiological pathway is very well developed and capable of 
processing very high amounts of citric acid as long as it occurs in   low concentrations. 
    Citric acid  in reaction with enzyme citratase /citrate lyase/ yields oxaloacetic acid & acetic acid. 
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  Cosmetics and pharmaceutical applications 
 
• Citric acid is widely used as a pH adjusting agent in creams and gels of all kinds. In this role, it is 
classified in most jurisdictions as a processing aid and so does not need to be listed on ingredient 
lists. 
• Citric acid is an alpha hydroxy acid and used as an active ingredient in chemical peels. 
• Citric acid is commonly used as a buffer to increase the solubility of brown heroin. Single-use 
citric acid sachets have been used as an inducement to get heroin users to exchange their dirty 
needles for clean needles in an attempt to decrease the spread of AIDS and hepatitis.[12] Other 
acidifiers used for brown heroin are ascorbic acid, acetic acid, and lactic acid; in their absence, a 
drug user will often substitute lemon juice or vinegar. 
• Citric acid is used as one of the active ingredients in the production of antiviral tissues.  
 
Dyeing 
 
  Citric acid can be used in food coloring to balance the pH level of a normally basic dye. It 
is used as an odorless alternative to white vinegar for home dyeing with acid dyes. 
 
Qualitative analysis 
 
 Sodium citrate, a conjugate base of citric acid, is used as a chelating agent and is present 
in the Benedict's reagent, used for identification both qualitatively and quantitatively, of reducing 
sugars. 
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6.  MATERIALS 
INGREDIENTS USED: 
S.NO MATERIALS SOURCE 
1. Zolmitriptan Aurobindo 
2. Aerosil Caboril 
3. Mannitol Spi Polyous ine 
4. Croscarmellose sodium DMV International 
5. Sodium Starch glycolate DMV International 
6. Crosspovidone BASF 
7. Peppermint Flavour LUX Flavour 
8. Sucralose TJTE and LYCE 
9. Magnesium stearate Sunshine Organics 
10 Talc Luzinac 
 
Table1 materials used for the experiment 
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FUNCTIONAL CATEGORIES OF EXCIPIENT 
Materials Category 
Zolmitriptan Active Pharmaceutical Ingredient 
Mannitol Diluents 
Aerosil Glidant 
Crospovidone Superdisintegrant 
Croscarmellose sodium Superdisintegrant 
Sodium starch glycolate Superdisintegrant 
Sucralose Sweetener 
Peppermint Flavour Flavour 
Magnesium stearate Lubricant 
Talc Lubricant 
 
Table 2 List of functional category of materials used 
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LIST OF EQUIPMENTS UTILIZED 
 
 
INSTRUMENTS 
 
MANUFACTURER 
Weighing Balance Precisa 205A 
FTIR IR Affinity-1 SHIMADZU 
Compression Machine CLIT Single Rotatory 16  Staionary 
Hardness tester Monsanto Hardness Tester-Cadmach 
Friabilator In lab Equipments 
Sieves Sethi Standard Test Sieves 
Vernier Calliper MIUTOYO 
UV-Spectrophotometer Tec comp UV 2300 
Dissolution apparatus, U.S.P. Electrolab Tab. Disso.tester USP–TDT– 06P 
Bulk Density Apparatus VEEGO 
HPLC LC-2010A HT-SHIMADZU 
PH meter Elchem 
Disintegration  Test Apparatus USP VEEGO Model-VTD-DV 
Magnetic Stirrer LASCO 
Sonicator Ultra Sonic Agitator-SAISONIC 
 
Table 3 List of Equipments Used 
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7. METHODOLOGY 
7.1 PREFORMULATION STUDIES 
Preformulation testing is an investigation of physical and chemical properties of drug 
substance alone and combined with pharmaceutical excipients.  It is the first step in the rational    
development of dosage form. 
 
7.1.1. Compatibility studies by FTIR studies (Fourier transform infrared spectroscopic 
studies)  
In the preparation of ODT tablet, drug and polymer may interact as they are in close 
contact  with  each  other,  which  could  lead  to  instability  of  drug.  Preformulation studies 
regarding drug-polymer interactions are therefore very critical in selecting appropriate polymers. 
FT-IR  spectroscopy  (AGILENT  TECHNOLOGIES)  was  employed  to  ascertain  the  
compatibility  between  Zolmitriptan  and  selected  polymers. The individual drug and drug with 
excipients were scanned separately.  
Procedure: 
 Potassium  bromide was  mixed with  drug and polymer  in the ratio of 100:1 and pellet  
was  prepared  using  KBr  pellet  press  and  spectrum  was  taken  using  FTIR  .  FT-IR 
spectrum of Zolmitriptan was compared with spectrum of Zolmitriptan and polymer.  
Disappearance  of  Zolmitriptan  peaks  or  shifting  of  peak  in  any  of  the  spectra was studied. 
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7.2 CHARACTERIZATION OF POWDER (50) 
 
PRECOMPRESSION STUDIES 
 
Prior to compression and blend was evaluated for their characteristic parameters such as: 
1. Angle of repose 
2. Bulk density 
3. Tapped density 
4. Compressibility index 
Angle of repose 
The angle of repose of blends was determined by the funnel method. The accurately 
weighed blend was taken in funnel. The height of the funnel was adjusted in such a way that the 
tip of the funnel just touched the apex of the heap of the blend. The blend was allowed to flow 
from the funnel on the surface. The diameter and height of the heap formed from the blend was 
measured. The angle of repose was calculated using following formula 
Tan = h/r ………… Eqn. (1) 
Where, “h” is height of the heap and “r” is the radius of the heap of granules. 
 Bulk density  
Bulk density is used as a measure to describe packing materials or granules. Bulk density 
is the ratio of given mass of powder and its bulk volume. It was determined by transferring an 
accurately weighed amount of powder sample to the graduated cylinder with the aid of a funnel. 
The initial volume was noted. Ratio of weight of the sample to the volume it occupied was 
calculated.      
Bulk density = W/V0 g/ml 
                                                       W= Mass of the blend 
                                                        V0 =Untapped volume 
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Tapped Density: 
Tapped density was measured by transferring a known quantity of blend into a graduated 
cylinder and was placed on the tapped density apparatus. The initial volume was noted. The 
apparatus was set for 500, 750 and 1250 taps. The tapped density was determined as the ratio of 
mass of the blend to the tapped volume. 
Tapped density=W/V f g/ml 
                                                       W= Mass of the blend 
                                                       Vf = Tapped volume 
 
 Compressibility index  
It is the propensity of a powder to be compressed. It is measured by tapped density 
apparatus for 500, 750 and 1250 taps for which the difference should be not more than 2%. 
Based on the apparent bulk density and tapped density the percentage compressibility of the 
blend was determined using the following formula. 
                                    % Compressibility = [(V0 – Vf) / V0] X 100 
                                                                   OR 
% Compressibility = [(Tapped density – Bulk density) / Tapped density] X100 
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7.3 FORMULATION OF TABLETS (51, 52) 
 DIRECT COMPRESSION 
Easiest way to manufacture tablets is direct compression, and advantages of direct compression   
is  
• Cost Effectiveness 
• Stability 
• Faster Dissolution 
• Less wear & tear of punches 
 However disintegration and dissolution of directly compressed tablets depend on single or 
combined effect of disintegrants, water soluble excipients and effervescing agents. It is essential 
to choose a suitable and an optimum concentration of disintegrants to ensure quick disintegration 
and dissolution.  
 
FORMULATION PROCEDURE: 
1.  Sieve Zolmitriptan, Mannitol through 40mm mesh by geometrical mixing and sieve,   
Crosscarmellose Sodium, Sucralose, Citric acid, Aerosil, talc, and Peppermint flavor through 40 
mesh and add above blend for 5 min. 
2.   And finally Magnesium Stearate was pass through the 40mm mesh and add to the above    
blend    for 2min. 
 3.   Finally the blend should be compressed in to tablets in single rotator compression machines: 
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INGREDIENTS(MG) F-1 F-2 
 
F-3 F-4 F-5 F-6 
Zolmitriptan 2.5mg 2.5mg 2.5mg 2.5 2.5 2.5 
Mannitol 68.5 58.5mg 72mg 69.5.mg 55.5 68.5 
Crosspovidone - - - - 30 20 
Crosscarmellose 
sodium(CCNA) 
- - 10mg 15mg - - 
Sodium starch 
glycolate(SSG) 
20mg 25mg - - - - 
Sucralose 2mg 4mg 5mg 4mg 3mg 2mg 
Citric acid 1mg 2mg 2mg 1mg 2mg 1mg 
Aerosil 2mg 2mg 2mg 3mg 1mg 2mg 
Talc 1mg 1mg 1mg 2mg 2mg 1mg 
Magnesium stearate 2 4 4mg 2mg 3mg 2mg 
Peppermint flavor 1mg 1mg 1mg 1mg 1mg 1mg 
                           Table 4 Formulation of Zolmitriptan Oral disintegration tablets  
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7.4 POST COMPRESSION STUDIES (53): 
 
Thickness  
 Thickness was determined for 20 pre-weighed tablets of each batch using a digital 
Vernier scale and the average thickness was determined in mm. The tablet thickness should be 
controlled within a ± 3% variation of a standard.  
 Weight variation  
   20 tablets were selected randomly from a batch and were individually weighed and then 
the average weight was calculated. The tablets meet the USP specifications if not more than 2 
tablets are outside the percentage limit and if no tablet differs by more than 2 times the 
percentage limits. 
 Hardness 
 The hardness of tablet is an indication of its strength. Measuring the force required to 
break the tablet across tests it. The force is measured in kg and the hardness of about 3-5 kg/cm2 
is considered to be satisfactory for uncoated tablets. Hardness of 10 tablets from each 
formulation is determined by Monsanto hardness tester, Pfizer hardness tester etc.  
Friability 
It is the measurement of mechanical strength of tablets. Roche friabilator was used to 
determine the friability by following procedure. A preweighed tablet was placed in the 
friabilator. Friabilator consist of a plastic-chamber that revolves at 25 rpm, dropping those tablets 
at a distance of 6 inches with each revolution. The tablets were rotated in the friabilator for at 
least 4 minutes. At the end of test tablets were dusted and reweighed, the loss in the weight of 
tablet is the measure of friability and is expressed in percentage as, 
% Friability = Loss in weight / Initial weight x 100 
% Friability = [(W0—Wf) / W0] ×100 
W0 = Initial weight of tablets 
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W f = Final weight of tablets 
= W0/Wv/W0×100. 
 
7.5 DISINTEGRATION TIME 
 
Disintegration time is the time taken by the tablet to breakup into smaller particles. The 
disintegration test is carried out in an apparatus containing a basket rack assembly with six glass 
tubes of 7.75 cm in length and 2.15 mm in diameter, the bottom of which consists of a #10 mesh 
sieve. The basket is raised and lowered 28-32 times per minute in a medium of 900 mL which is 
maintained at 37±2 °C. Six tablets were placed in each of the tubes and the time required for 
complete passage of tablet fragments through the mesh (# 10) was considered as the 
disintegration time of the tablet. The disintegration time that patients can experience for oral 
disintegrating tablets ranges from 5 to 30 seconds.  
 
7.6 DISSOLUTION STUDIES 
 
Standard preparation 
 
  Weigh accurately 25 mg of Standard Zolmitriptan into a 50 mL volumetric flask, dissolve 
and make up the volume with 0.1N HCl. Transfer 1 mL of the solution into a 100 mL volumetric 
flask and make up the volume with the 0.1N HCl. The solution contains 5 µg/ mL respectively. 
Scanned 283 nm by UV spectroscopy. 
 
Test: 
 
Dissolution is a process by which the disintegrated solid solute enters the solution. The 
test determines the time required for a definite percentage of the drug in a tablet to dissolve 
under specified conditions. The dissolution test was carried out in USP Apparatus Type II 
(paddle) with 0.1 N Hydrochloric acid as the dissolution medium. The samples were drawn at 5, 
10, 15, 20, 30, min. Fresh volume of the medium were replaced with the withdrawn volume to 
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maintain the sink conditions. Samples withdrawn were analyzed for the percentage of drug 
released. 
  
Dissolution Parameters: 
Dissolution Apparatus :  USP Apparatus Type II (Paddle) 
Dissolution Medium  :  0.1N Hydrochloric acid 
Volume                               :   500 ml 
Temperature                        :   37±2° C 
Rpm                                  :   50 
Sampling Intervals (min)     :   5, 10, 15, 20, 30 min. 
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7.7 DRUG CONTENT ESTIMATION (54) 
ESTIMATION BY HPLC METHOD 
 
Mobile phase           :         Buffer CH3OH (750:250). 
Buffer                      :        750 ml of 0.01M K2HPO4+2ML OF Tri ethylamine. 
PH                           :        7.5 with H3PO4 
Flow Rate                :         1.5 ml/min 
Column                    :         C18, 150+4.6 M. 
X                              :         230 nm. 
Load                         :         20 µl. 
 
STANDARD PREPARATION: 
 
Accurately weigh and transfer 50 mg of Zolmitriptan working standard into a 50 ml 
volumetric flask add about 25 ml of mobile phase and sonicate to dissolve it completely and 
make volume up to the mark with the same solvent. Further pipette 5 ml of the above prepared 
solution into a 50 ml volumetric flask and dilute up to the mark with diluents. Mix well and filter 
through 0.45 µm filter. 
 
Sample Solution Preparation 
 
Accurately weigh and transfer 50 mg of Zolmitriptan sample powder into a 50 ml 
volumetric flask add about 25 ml of mobile phase and sonicate to dissolve it completely and 
make volume up to the mark with the same solvent. Further pipette 5 ml of the above prepared 
solution into a 50 ml volumetric flask and dilute up to the mark with diluents. Mix well and filter 
through 0.45µm filter. 
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KINETIC RELEASE STUDIES 
    
                  Statistical analysis of the different properties of the formulations was performed, 
Using the one way analysis of variance (ANOVA), Along with the tucky post test. For this 
purpose graph Pad instat software version 3.0.1 was used. A statistical significance was defined 
at p<0.05. 
 
Kinetic analysis of in vitro release rates of formulations (55 ,56). 
 
The results in vitro release profile obtained for all the formulations were plotted in modes of data 
treatment as follows:- 
1. Zero-order kinetic model-cumulative percentage drug release versus time. 
2. First order kinetic model-log cumulative percentage drug release remaining versus time. 
3. Higuchi’s model-cumulative percentage drug released versus square root of time 
4. Korsmeyer’s equation/peppa’s model-log cumulative percentage drug released versus log 
time. 
 
1. Zero-order kinetics 
 
Zero order release would be predicted by the following equation:- 
At = A0-K0t 
Where, 
At=drug release at time ‘ t’ 
A0=Initial drug concentration 
K0=Zero order rate constant (hr-1) 
 
When the data is plotted as cumulative percent drug release versus time, if the plot is linear then 
the data obeys zero order release kinetics, with a slope equal to k0. 
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2. First order kinetics    
 
First order release would be predicted by the following equation:- 
                             
Log c=log c0-kt/2.303 
Where, 
 
C=amount of drug remained at time t’. 
C0=initial amount of drug 
K=first-order rate constant (hr-1) 
 
When the data is plotted as log cumulative percent drug remaining versus time yields a 
straight line, indicating that the release follows first order kinetics. The constant k can be 
obtained by multiplying 2.303 with slope values. 
 
3. Higuchi model  
 
 Drug release from the matrix devices by diffusion  has been described by following higuchi’s 
classical diffusion equation. 
                           
Q = (Dε/τ(2A-εCS)Cst)1/2 
where, 
                             Q= amount of drug release at time‘t’ 
                             D=diffusion coefficient of drug in the matrix 
                             A=total amount of drug in unit volume of matrix 
                            Cs=the solubility of drug in the matrix 
                             ε=porosity of the matrix 
                             τ=time (hrs) at which Q amount of drug is released 
 
Above equation may be simplified if one assumes that D, Cs, and A, are constant. 
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Then equation  becomes 
Q = K t1/2 
When the data is plotted according to equation i.e cumulative drug release versus . Square 
root of time yields a straight line, indicating that the drug was released by diffusion mechanism. 
The slope is equal to ‘k’. 
 
4. korsemeyer equation / peppa’s model) 
  
Equation/peppas law equation) which  is often to describe the drug release behavior from 
polymeric systems. 
 
Mt/Ma = ktn 
Where, 
                                  
                    Mt/Ma=the fraction of drug released  at time ‘t’     
       K=constant incorporating the structural and geometrical characteristics of   the  
drug/polymeric. 
                  N=diffusion exponent related to the mechanism of release 
Above equation can be simplified by applying log on both sides, and we get: 
                          
log Mt/ Ma = log k +n log t 
When the data is plotted as log of drug release versus log time, yields a straight line with 
a slope equal to ‘n’ and the ‘k’ can be obtained from y-intercept. For Fickian release ‘n’=0.5 
while for anomalous (non-Fickian ) transport ‘n’ ranges from 0.5 to 1.0 as shown below. 
 
 Table: 5 Mechanism of drug release as per Korsemeyer equation/ Peppa’s model. 
               S.No               n Value              Drug release 
                  1.               n<0.5 Fickians release 
                  2.              0.5<n<1 Non fickians release 
                  3.                n>1 Case 11 transport 
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8.  RESULTS 
 
8.1 Preformulation Studies 
 
 8.1.1 Compatibility studies (Fourier transform infrared spectroscopic studies) 
 
Potassium Bromide pellet method was used in the study. Test samples were prepared by 
physical mixing of Zolmitriptan and excipients in ratios of 1:1 Initially.100mg of potassium 
bromide power was mixed with 2mg of each sample, thoroughly triturated in mortar and pestle. 
A portion of mixture was compressed using IR pelletizing press. Then the KBR pellet was 
placed in sample holder of Bruker FT-IR spectrophotometer. The spectra were recorded in the 
wave number region of 4000-500cm-1. In each case the spectra was compared with the pure 
zolmitriptan spectrum to detect the interactions between drug and excipients. 
                The FTIR Graphs of drug and excipients were shown in the figures  
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Standard calibration curve of zolmitriptan54: 
Weigh 50 mg of pure drug Zolmitriptan and is dissolved in 0.1N HCL solution and from 
this solution the series concentrations prepared (4,8,12,16,20 µg/ml)  and absorbance is noted at 
267nm. 
 
S.no Concentration(µg/ml) Absorbance 
1 0 0 
2 1 0.152 
3 2 0.286 
4 4 0.572 
5 6 0.865 
6 8 1.119 
 
Table 6: Standard calibration curve values of Zolmitriptan 
 
 
Fig 16 Standard Calibration Curve of Zolmitriptan 
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Preformulation studies 
 
  Table7: Pre formulation evaluation parameters of all the formulations of Zolmitriptan 
S.No Formulation Angle of 
repose(0) ±SD 
 
Bulk 
Density 
(g/ml)±SD 
 
Tapped 
Density 
(g/m) ±SD 
Carr’s index 
± SD 
1 F1 270.54±0.04 0.49±0.03 0.56±0.03 15.69 
2 F2 270.38 ±0.06 0.53±0.04 0.57±0.01 16.28 
3 F3 290.73±0.09 0.45±0.01 0.54±0.03 16.28 
4 F4 260.66±0.36 0.49±0.01 0.52±0.02 15.18 
5 F5 26о.85'± 0.24 0.47±0.02 0.90±0.03 47.63 
6 F6 26º.08'±'0.36 0.43±0.01 0.76±0.02 43.42 
 
 From the above pre compression parameters the blends showed good flow properties and the  
excepients didn’t show any effect. 
 
  Post formulation studies 
Table 8: post formulation evaluations of all the formulation of Zolmitriptan 
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S.No 
 
Formulation 
Weight 
variation 
test(gm) 
Thickness 
test 
(mm) 
 
Hardness 
test 
(Kg/Cm2) 
 
 
Friability 
test 
(%) 
 
Disintegrating 
g Time (sec) 
1 F1 0.646±3 2.0±0.02 2.9 0.27 53±2 
2 F2 0.701±2 1.8±0.02 2.5 0.4 45±3 
3 F3 0.765±4 1.8±0.02 2.6 0.37 47±4 
4 F4 0.684±2 1.9±0.01 2.3 0.46 43±2 
5 F5 0.102±4 2.97±0.01 4 2.4 20±3 
6 F6 0.097±3 2.95±0.01 3.5 2.8 15±4 
                   
From the above post compression parameters of all the six formulations are found to be 
within the limit 
DISINTEGRATION TEST: 
 
 
    Fig17: The disintegration 
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DISSOLUTION TEST: 
 
Table 9: In vitro drug release of (F1) Zolmitriptan 
 
 
TIME(Min) 
 
Trail 1 Trail 2 Trail 3 Mean ±S.D 
0 0 0 0 
 
0 
 
0 
5 56.3 53.6 53.2 54.36 1.686 
10 68.7 67.9 69.2 68.6 0.655 
15 72.9 73.9 74.8 73.86 0.950 
30 79.6 80.1 80.8 80.16 0.602 
 
N=3 Each value represents the mean ± S.D of three experiments  
 
 
 Table 10: Percentage drug release formulation of Zolmitriptan oral disintegrating tablet 
 
 
Time 
 
 
Absorbance 
(nm) 
 
Concentration 
 
 
Amount of 
drug 
release 
 
Amount of 
drug 
release/500 
 
Cumulative 
drug release 
 
% Drug 
release 
0 0 0 0 0 0 0 
5 0.019 0.135 0.002 1.35 1.35 54.39 
84 
 
10 0.024 0.171 0.0034 1.71 1.71 68.68 
15 0.026 0.185 0.003 1.85 1.86 74.42 
30 0.028 0.2 0.004 2 2.00 80.16 
 
N=3 Each value represents the mean ± S.D of three experiments 
 
    
Table 11: Kinetic drug release formulation of Zolmitriptan oral disintegrating tablet 
 
Square  
root Log time 
% Drug 
release 
log% Drug 
release 
% Drug 
remaining 
 
log % Drug 
remaining 
 
2.236 0.69 54.3 1.7 45.7 1.65 
3.162 1 68.6 1.83 31.4 1.49 
3.872 1.17 74.4 1.87 25.6 1.40 
5.477 1.47 80 1.90 20 1.30 
 
N=3 Each value represents the mean ± S.D of three experiments 
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Fig: 19 
 
Fig: 20 
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Fig: 21 
 
 
Fig: 22 
 
 
 Table: 12 In vitro drug release of (F2) Zolmitriptan  
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TIME(Min) 
 
Trail 1 Trail 2 Trail 3 Mean S.D 
0 0           0 0 
 
0 
 
0 
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N=3 Each value represents the mean ± S.D of three experiments 
 
Table: 13 Percentage drug release formulation of Zolmitriptan oral disintegrating tablet 
 
Time Absorbance Concentration 
Amount 
of drug  
release 
 
 
Amount 
of drug 
release 
mg/500 
 
Cummulative 
drug release 
% of 
drug 
release 
 
0 
 
0 0 0 0 0 0 
5 
 
0.022 0.157 0.003 1.57 1.574 62.98 
10 
 
0.025 0.178 0.003 1.78 1.788 71.55 
15 
 
0.026 0.185 0.003 1.85 1.860 74.42 
 
30 
 
0.029 0.207 0.004 2.07 2.075 83.02 
 
N=3 Each value represents the mean ± S.D of three experiments 
 
 
 
5 61.8 62.7 64.2 62.9 1.21 
10 70.8 71.6 72.2 71.53 0.701 
15 73.8 74.7 74.9 74.46 0.585 
30 79.9 84.2 84.9 83 2.707 
  Table 14: Kinetic drug release formulation of Zolmitriptan oral disintegrating tablet
 
 
Square  root 
 
Log time 
2.236 0.698 
3.162 1 
3.872 1.176 
5.477 1.477 
N=3  Each value represents the mean ± S.D of three experiment
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% Drug 
release 
log% Drug 
release 
% Drug  
remaining
62.9 1.798 37.1 
71.5 1.854 28.5 
74.4 1.871 25.6 
83.2 1.920 16.8 
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Fig: 25 
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Table: 15 In vitro drug release of (F3) Zolmitriptan 
 
 
TIME(Min) 
 
Trail 1 Trail 2 Trail 3 Mean ±S.D 
0 0 0 
 
0 
 
0 
 
0 
5 64.9 65.9 66.7 65.83 0.90 
10 70.8 71.6 72.2 71.53 0.70 
15 76.5 77.3 77.8 77.2 0.65 
 
30 84.9 85.8 86.7 85.8 0.9 
 
N=3 Each value represents the mean ± S.D of three experiments 
 
Table: 16 Percentage drug release formulation of Zolmitriptan oral disintegrating tablet 
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Time 
 
Absorbance Concentration 
Amount 
drug  
release 
 
Amount 
of drug 
release 
mg/500 
 
Cummulative 
drug release 
% 
Drug 
release 
0 0 0 0 0 
 
0 
 
0 
5 0.023 0.164 0.003 1.642 1.646 65.84 
10 0.025 0.178 0.003 1.785 1.789 71.56 
15 0.027 0.192 0.003 1.928 1.932 77.28 
30 0.03 0.214 0.004 2.142 2.147 85.88 
 
N=3 Each value represents the mean ± S.D of three experiments  
 
   
 
 
 
 
 
Table: 17 Kinetic drug release formulation of Zolmitriptan oral disintegrating tablet 
 
 
Square root 
 
 
Log time % Drug 
release 
log% Drug 
release 
% Drug 
remaining 
log % Drug 
remaining 
2.236 0.698 65.8 1.818 34.2 1.534 
3.162 1 71.5 1.854 28.5 1.454 
3.872 1.176 77.2 1.887 22.8 1.357 
5.477 1.477 85.8 1.933 14.2 1.152 
                    
N=3    Each value represents the mean ± S.D of three experiments
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Fig: 28 
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Fig: 31 
 
 
Fig: 32 
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Table: 18 In vitro drug release of (F4) Zolmitriptan 
 
 
TIME(Min) 
 
Trail 1 Trail 2 Trail 3 Mean ±SD 
0 0 0 0            0 
           0 
5 69.8 71.8 72.9 71.5 1.571 
10 73.7 74.5 75.1 74.43 0.702 
15 78.3 80.1 82.1 80.14 1.900 
30 87.5 88.9 89.9 88.60 1.205 
 
N=3 Each value represents the mean ± S.D of three experiments  
 
Table: 19 Percentage drug release formulation of Zolmitriptan oral disintegrating tablet 
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Time 
 
Absorbance 
 
Concentration 
 
Amount 
of  drug  
release 
 
 
 
Amount 
of drug  
release 
mg/500 
 
Cummulative 
drug  release 
% Drug 
release 
0 0 0 0 0 0 0 
5 0.025 0.178 0.003 1.785 1.789 71.57 
10 0.026 0.185 0.003 1.857 1.860 74.42 
15 0.028 0.2 0.004 2 2.003 80.14 
30 0.031 0.221 0.004 2.214 2.218 88.6 
 
N=3 Each value represents the mean ± S.D of three experiments  
 
 
 
 
 
 
 Table: 20 Kinetic drug release formulation of Zolmitriptan oral disintegrating tablet 
 
 
Square root 
 
Log time % Drug 
release 
Log% drug 
release 
 
% Drug  
remaining 
 
Log % drug 
remaining 
2.236 0.698 27.95 1.446 72.041 1.857 
3.162 1 40 1.602 60 1.778 
3.872 1.176 47.043 1.672 52.956 1.723 
5.477 1.477 88.6 1.947 11.4 1.056 
 
N=3 Each value represents the mean ± S.D of three experiments 
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Fig: 33 
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Table: 21 In vitro drug release of (F5) Zolmitriptan 
 
 
TIME(Min) 
 
Trail 1 Trail 2 Trail 3 Mean ±SD 
0 0 0              0 
 
0 
 
0 
5 78.3 80.1 82.1 80.16 1.90 
10 90 92.1 92.6 91.56 1.379 
15 96.5 97.7 97.9 97.3 0.757 
30 98.8 98.4 98.9 98.7 0.264 
   
N=3    Each value represents the mean ± S.D of three experiments  
 
Table: 22 Percentage drug release formulation of Zolmitriptan oral disintegrating tablet 
 
Time 
 
 
 
 
 
Absorbance 
 
 
 
 
 
 
Concentration 
 
 
 
 
 
Amount  
of drug  
release 
 
 
 
Amount  
of drug  
release 
mg/500 
 
Cummulative 
drug  release 
 
 
% Drug 
release 
 
 
0 0 0 0 0 0 
 
0 
5 0.028 0.2 0.004 2 2.004 80.16 
10 0.032 0.228 0.004 2.285 2.289 91.58 
15 0.034 0.242 0.004 2.428 2.433 97.32 
30 0.034 0.246 0.004 2.464 2.469 98.76 
 
99 
 
N=3 Each value represents the mean ± S.D of three experiments  
 
  
 
 
 
 
 
Table: 23 Kinetic drug release formulation of Zolmitriptan oral disintegrating tablet 
 
Square root 
 
Log time % Drug 
release 
Log% drug 
release 
% Drug  
remaining 
 
log % Drug 
remaining 
 
2.236 0.698 80.1 1.903 19.9 1.298 
3.162 1 91.5 1.961 8.5 0.929 
3.872 1.176 97.3 1.988 2.7 0.431 
5.477 1.477 98.7 1.994 1.3 0.113 
 
N=3 Each value represents the mean ± S.D of three experiments 
 
 Fig:  38 
 0
20
40
60
80
100
120
0
Invitro drug release of F5(Zolmitriptan)
0
20
40
60
80
100
120
0
C
u
m
u
la
ti
v
e
 %
 d
ru
g
 r
e
le
a
se
Zero order plot of F5(Zolmitriptan)
100 
 
Fig: 39 
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Fig: 41 
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 Table: 24 In vitro drug release of (F6) Zolmitriptan 
 
 
TIME(Min) 
 
Trail 1 Trail 2 Trail 3 Mean ±SD 
0 0 0 0 
               
            0 
           
          0 
5 81.6 83.4 84.2 83.06 1.33 
10 92.8 94.8 95.6 94.4 1.44 
15 96.5 97.7 97.9 97.36 0.75 
30 98.8 98.2 99.8 99.06 1.02 
                    
    N=3     Each value represents the mean ± S.D of three experiments  
 
                                                                                               
Table: 25 Percentage drug release formulation of Zolmitriptan oral disintegrating tablet 
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   Time 
 
 
Absorbance Concentration 
Amount 
of  drug  
release 
Amount 
of  drug 
release 
mg/500 
Cummulative 
drug  release 
% Drug 
release 
0 0 0 0 0 0 0 
5 0.029 0.207 0.004 2.071 2.075 83.02 
10 0.033 0.235 0.004 2.357 2.361 94.45 
15 0.034 0.242 0.004 2.428 2.433 97.33 
30 0.035 0.25 0.005 2.5 2.505 99 
 
N=3 Each value represents the mean ± S.D of three experiments  
 
 
 
 
 
 
 
Table: 26 Kinetic drug release formulation of Zolmitriptan oral disintegrating tablet 
 
Square root Log time % Drug    
release 
 
Log% drug 
release 
 
% Drug  
remaining 
log % Drug  
remaining 
2.236 0.698 83 1.919 17 1.230 
3.162 1 94.4 1.974 5.6 0.748 
3.872 1.176 97.3 1.988 2.7 0.431 
5.477 1.477 99 1.995 1 0 
Each value represents the mean ± S.D of three experiments 
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Fig: 43 
 
Fig: 44 
 
 
 
 
Fig: 45 
10 20 30 40
%drug release
y = 0.522x + 85.58
R² = 0.614
10 20 30 40
Time(min)
105 
 
 
 
Fig: 46 
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Table: 27 COMPARATIVE STUDY OF INVITRO % DRUG RELEASE PROFILE OF 
ZOLMITRIPTAN ORAL DISINTEGRATING TABLETS: 
 
TIME 
 
F1 F2 F3 F4 F5 F6 
0 
 
0 
 
0 0 0 
 
0 
 
0 
5 54.36 62.9 66.7 71.5 80.16 83.06 
10 68.6 71.53 72.2 74.43 91.56 94.4 
15 73.86 74.46 77.8 80.14 97.3 97.36 
30 80.16 83 86.7 88.6 98.7 99.06 
 
Fig: 48 
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TABLE: 28 Kinetic Values Obtained from Different Plot of Formulation (F
 
 
 
Formulati
on Code 
Zero 
order 
plot 
First 
order plot
R2 R2 
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1
 
Higuchi’s 
plot 
Korsemeyer peppas 
plot Possible mechanism 
of drug
R2 R2 n 
10 20 30 40
RELEASE
time 
 
To F6) 
 release 
F3
F4
F5
F6
F1
F2
108 
 
F1 0.690 0.728 0.868 0.987 0.052 Fickian release 
F2 0.629 0.896 0.976 0.972 0.002 Fickian release 
F3 0.687 0.953 0.994 0.95 0.063 Fickian release 
F4 0.846 0.969 0.979 0.945 0.065 Fickian release 
F5 0.893 0.988 0.772 0.968 0.089 Fickian release 
F6 0.614 0.998 0.733 0.998 0.051 Fickian release 
 
 
 
 
 
 
 
 
 
 
 
 
 
DRUG CONTENT ESTIMATION OF ZOLMITRIPTAN FORMULATION (54) 
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Fig: 49 Chromatograms of Zolmitriptan Oral disintegration tablet 
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Table: 29 
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TABLE: 30 Assay of formulation (F6) Zolmitriptan oral disintegrating 
tablets 
 
 
 
Assay 
 
 
 
 
S.No 
 
Standard Test A1 TestA2 
1 6192129 5932532 5907691 
2 6202065 5941328 5915152 
3 6217339   
4 6198350   
5 6197642   
6 6265651   
 
Average 
 
6212196 
 
5936930 
 
5911422 
 
 
S.D 
 
27541.75 
 
6219.71 
 
5275.72 
 
 
%RSD 
 
0.44 
 
0.10 
 
0.09 
 
%Assay 
  
 
95.92 
 
95.99 
 
 
Drug 
content(mg) 
 
  
2.430057 
 
2.419616 
112 
 
=Test area/std area*50/50*5/50*100/393.2*100/2.5*99.16 
Drug             
 content     = Test area/std area*50/50*5/50*100/393.2*99.98/100*100 
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                                                 9. DISCUSSION 
 
Zolmitriptan is a serotonin receptor agonist  used in the acute treatment 
of migraine attacks Conventional Zolmitriptan not suitable where quick onset of action is 
required. To overcome these problems, there is a need to develop oral disintegrating dosage 
form, particularly one that would rapidly disintegrate in saliva and could be administered without 
water anywhere anytime.  
  
The oral disintegrating tablets of Zomitriptan were prepared by direct compression 
superdisintegrants addition method using Sodium starch glycolate, Crospovidone and  
Croscarmellose sodium in different concentrations.  There are total six formulations (F1 to F6) 
were prepared and evaluated for Weight variation, Thickness, Friability, Hardness, 
Disintegration time, and  dissolution study.  
 
Results of all formulations showed the drug release rate was increased when the super 
disintegrants were used in combination and alone. . The Weight variation, Friability, Hardness 
and drug content were found to be within the limit and no significant variation. The 
Disintegration time for F1-F6 formulations was found to be 10 to 30 seconds. Based on the In-
vitro dissolution percentage% of drug release of the formulation F1-F6 shows( 80.16%-99.06%) 
.The formulation f6 showed maximum drug release within 10 minutes (94.4%) and F6 
containing Crosspovidone as a superdisintegrant showed minimum disintegration time 15 
seconds. The results shows the disintegration time was increased in the following manner. 
   
Crosspovidone  > Crosscarmellose sodium  >  sodium starch glycolate. 
 
Based on the results the best formulation (F6) shows the drug content 95.9%. 
In all the f1-f6 formulation are subjected to the release kinetics. In the kinetic results shows, best 
fit in first order drug release and followed by the ‘n’ value shows between (0.002-0.089), follows 
Fickian’s release mechanism 
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                                                      10. CONCLUSION 
 
 The oral disintegrating tablets of Zolmitriptan were prepared by using different super 
disintegrants in different ratios. Based on the study concluded that the F6 formulation by using 
Zolmitriptan and superdisintegrants Crosspovidone shows maximum drug content and invitro  
percentage drug release, and faster disintegration time. 
 And all the formulations shows first order release kinetics and best fit into Fickian’s 
release mechanism. 
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